DNA nanotubes by Sellner, Sabine
 Aus dem Institut für Chirurgische Forschung 
(im Walter-Brendel-Zentrum für Experimentelle Medizin) 
der Ludwig-Maximilians-Universität München 
Vorstand Prof. Dr. med. Ulrich Pohl 
 
 
DNA nanotubes - intracellular delivery vehicles in vivo 
 
 
 
 
 
DISSERTATION 
zum Erwerb des Doktorgrades der Naturwissenschaften 
an der Medizinischen Fakultät der 
Ludwig-Maximilians-Universität zu München 
 
 
 
 
Vorgelegt von  
Sabine Sellner 
  
aus Freyung  
 
2016 
 
 
 
 
 
 
 
 Mit Genehmigung der Medizinischen Fakultät 
der Universität München 
 
 
 
 
 
Berichterstatter:                             PD Dr. rer. nat. Markus Rehberg 
 
 
 
Mitberichterstatter:                        PD Dr. rer. nat. Silke Meiners 
         
                                                       Prof. Dr. rer. nat. Elfriede Nößner 
      
       Prof. Dr. rer. nat. Ludger Klein 
 
 
Dekan:                                            Prof. Dr. med. dent. Reinhard Hickel 
 
 
 
Tag der mündlichen Prüfung:        15.02.2017 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Eidesstattliche Versicherung 
 
 
Sellner, Sabine 
Name, Vorname 
 
 
 
Hiermit erkläre ich an Eides statt, dass ich die vorliegende Dissertation mit dem Thema: 
 
DNA nanotubes - intracellular delivery vehicles in vivo 
 
selbstständig verfasst, mich außer der angegebenen keiner weiteren Hilfsmittel bedient und 
alle Erkenntnisse, die aus dem Schrifttum ganz oder annähernd übernommen sind, als 
solche erkenntlich gemacht und nach ihrer Herkunft unter Bezeichnung der Fundstelle 
einzeln nachgewiesen habe. 
 
Ich erkläre des Weiteren, dass die hier vorgelegte Dissertation nicht in gleicher oder 
ähnlicher Form bei einer anderen Stelle zur Erlangung eines akademischen Grades 
eingereicht wurde. 
 
 
 
München, den  
Ort, Datum                                                                             Unterschrift Doktorandin 
 
 
 
 
 
 
 
Eidesstattliche Versicherung                                                                  Stand: 31.01.2013  
 
 
„Man sieht oft etwas hundert Mal, 
 tausend Mal, 
 ehe es man zum allerersten Mal 
wirklich sieht.“ 
Christian Morgenstern 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Contents 
 
1 Abstract ............................................................................................................................. 1 
1.1 Abstract ....................................................................................................................... 2 
1.2 Zusammenfassung ...................................................................................................... 5 
2 Introduction ...................................................................................................................... 8 
2.1 Nanotechnology ........................................................................................................... 9 
2.2 Biological and medical applications of NPs .................................................................. 9 
2.3 DNA nanotechnology ..................................................................................................10 
2.4 DNA nanostructures as drug delivery vehicles ............................................................13 
2.5 Monocytes and macrophages .....................................................................................15 
2.5.1 Monocytes ............................................................................................................15 
2.5.2 Tissue-resident macrophages...............................................................................16 
2.5.3 Activation and polarization of macrophages ..........................................................18 
2.6 Leukocyte recruitment from the microcirculation .........................................................19 
2.7 Ischemia-reperfusion injury .........................................................................................22 
2.8 Toll-like receptor 9 ......................................................................................................23 
2.9 Aim of the study ..........................................................................................................25 
3 Material and Methods ......................................................................................................26 
3.1 Material .......................................................................................................................27 
3.2 Methods ......................................................................................................................27 
3.2.1 Design and assembly of DNA nanotubes .............................................................27 
3.2.1.1 Design of 8-helix DNA nanotubes ..................................................................27 
3.2.1.2 Design of 6-helix DNA nanotubes ..................................................................28 
3.2.1.3 Dexamethasone conjugation ..........................................................................28 
3.2.1.4 Enzymatic dye labeling of tiles .......................................................................29 
3.2.1.5 DNA nanotube assembly and purification .......................................................30 
3.2.1.6 Gel electrophoresis and transmission electron microscopy ............................30 
3.2.1.7 Stability of DNA nanotubes ............................................................................31 
3.2.1.8 Gel electrophoresis to test the functionality of pH-responsive Dex tubes........31 
3.2.2 Cell culture ...........................................................................................................32 
3.2.2.1 RAW 264.7 cells ............................................................................................32 
3.2.2.2 Stimulation of RAW 264.7 cells ......................................................................32 
3.2.2.3 MH-S cells .....................................................................................................33 
3.2.2.4 Flow cytometry ...............................................................................................33 
3.2.2.5 Enzyme-linked immunosorbent assay (ELISA) ...............................................33 
  
3.2.2.6 Water-soluble tetrazolium salt (WST) cell viability assay ................................34 
3.2.3 In vivo imaging .....................................................................................................34 
3.2.3.1 Animals ..........................................................................................................34 
3.2.3.2 Surgical procedure .........................................................................................35 
3.2.3.3 Mouse model of I/R ........................................................................................36 
3.2.3.4 In vivo microscopy .........................................................................................37 
3.2.3.5 Microinjection of DNA nanotubes and LysoTracker dye .................................37 
3.2.3.6 Quantification of leukocyte kinetics and microhemodynamic parameters .......38 
3.2.3.7 Immunostaining ..............................................................................................39 
3.2.3.8 CpG DNA nanotubes in vivo ..........................................................................40 
3.2.3.9 CpG DNA nanotubes in vivo during I/R injury .................................................40 
3.2.3.10 Dex nanotubes in vivo during I/R injury ........................................................40 
3.2.4 Statistical analysis ................................................................................................41 
4 Results .............................................................................................................................42 
4.1 DNA nanotubes as intracellular delivery vehicles in vivo .............................................43 
4.1.1 Design, assembly, and characterization of DNA nanotubes ..................................43 
4.1.2 Release of inflammatory cytokines after stimulation with DNA nanotubes and 
ODNs in vitro .................................................................................................................47 
4.1.3 Localization of DNA nanotubes in skeletal muscle tissue after microinjection .......51 
4.1.4 Microinjection of CpG tubes induced leukocyte adhesion and transmigration .......53 
4.1.5 Mast cell inhibition abolishes CpG tube-evoked leukocyte adhesion and 
transmigration ...............................................................................................................56 
4.1.6 Systemic leukocyte counts and microhemodynamic parameters ..........................57 
4.1.7 CpG tube microinjection results in NF-ĸB pathway activation ...............................58 
4.2 The impact of CpG nanotubes on I/R injury .................................................................59 
4.2.1 Microdistribution of CpG DNA nanoconstructs in postischemic muscle tissue ......59 
4.2.2 Microinjection of CpG tubes into ischemic muscle tissue attenuates leukocyte 
adhesion and transmigration .........................................................................................61 
4.2.3 Systemic leukocyte counts and microhemodynamic parameters ..........................63 
4.2.4 Microinjection of CpG tubes into postischemic muscle tissue increases cellular 
TLR 9 expression ..........................................................................................................64 
4.3 Dexamethasone-conjugated DNA nanotubes as anti-inflammatory agents in vivo ......66 
4.3.1 Characterization and functionality of Dex nanotubes ............................................66 
4.3.2 Dexamethasone-conjugated DNA nanoconstructs do not affect macrophage 
viability ..........................................................................................................................68 
  
4.3.3 Dex tubes are effectively incorporated by macrophages .......................................69 
4.3.4 Dex tubes attenuate LPS-induced TNF secretion by MH-S macrophages ............73 
4.3.5 Microinjection of Dex tubes into postischemic muscle tissue lowers the number of 
adherent and transmigrated leukocytes .........................................................................74 
4.3.6 Systemic leukocyte counts and microhemodynamic parameters ..........................77 
4.3.7 Dexamethasone-conjugated nanoconstructs are phagocytosed and stored in 
endolysosomal compartments of tissue-resident cells ...................................................78 
4.3.8 Modulation of VCAM-1 and ICAM-1 expression by dexamethasone-conjugated 
nanoconstructs ..............................................................................................................79 
5 Discussion .......................................................................................................................83 
5.1 DNA nanotubes as intracellular delivery vehicles in vivo .............................................84 
5.2 The impact of CpG DNA nanotubes on I/R injury ........................................................87 
5.3 Dex tubes as anti-inflammatory agents in vivo ............................................................90 
5.4 Conclusion and future prospective ..............................................................................95 
6 References .......................................................................................................................97 
7 Appendix ........................................................................................................................ 110 
7.1 Lab equipment and consumables ............................................................................. 111 
7.2 Cell culture consumables .......................................................................................... 112 
7.3 Immunohistochemistry consumables ........................................................................ 113 
7.4 Abbreviations ............................................................................................................ 115 
7.5 Publications and presentations ................................................................................. 118 
7.5.1 Publications ........................................................................................................ 118 
7.5.2 Oral presentations .............................................................................................. 119 
7.5.3 Poster presentations ........................................................................................... 120 
7.6 Curriculum vitae ...................................................... Fehler! Textmarke nicht definiert. 
8 Acknowledgements ..................................................... Fehler! Textmarke nicht definiert. 
 
  
 
 
 
 
 
 
 
 
1 Abstract 
 
 
  
1 Abstract 
 
2 
 
1.1 Abstract 
 
The biomolecule deoxyribonucleic acid (DNA) plays an essential role in the 
development, function, and reproduction of living organisms. Furthermore, DNA is a 
natural polymer with unique properties used as raw material for several 
developments in the physical, medical, and biological sector. The structure of DNA 
makes it a programmable, functional, and biocompatible basic material for the 
production of precise structures in the nanometer range. DNA-based nanoconstructs 
offer great potential to be used as carrier systems for biomedical applications. 
However, their impact on biological systems and their distribution in cells and tissue 
is largely unknown.  
Therefore, DNA nanotubes with different ligands were produced, using the single-
stranded tile method, based on the self-organization of complementary 
oligonucleotides (ODNs) to tube-like structures in nanometer precision. The 
functionality and the microdistribution of these DNA structures were investigated 
under physiological and pathological conditions in the murine muscle tissue and in 
cultured macrophages. 
The use of DNA nanotubes as carrier systems, targeting macrophages in the murine 
skeletal muscle and their capacity to induce an immune response, was determined in 
the first part of this thesis. These DNA nanotubes were decorated with immunogenic, 
unmethylated cytosine-phosphate-guanine (CpG) DNA sequences which are specific 
for bacterial DNA and are recognized by the innate immune system of vertebrates. 
The detection of CpG sequences via the endosomal Toll-like receptor 9 (TLR 9) in 
macrophages after incubation with CpG DNA nanotubes led to the secretion of the 
proinflammatory cytokine tumor necrosis factor (TNF), while incubation with plain 
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nanotubes did not induce a significant immune response. To confirm the 
immunogenic effect of CpG DNA nanotubes in vivo, the constructs were 
microinjected into the murine cremaster muscle. All constructs were taken up by 
tissue-resident macrophages equally, but only microinjection of CpG DNA nanotubes 
caused nuclear translocation of the proinflammatory transcription factor NF-ĸB and 
the recruitment of leukocytes to the site of injection. 
Since DNA nanotubes were selectively ingested by tissue-resident macrophages and 
because the application of functional CpG motifs specifically affected the immune 
reaction of macrophages and mast cells, CpG DNA nanotubes were investigated 
under sterile inflammatory conditions in the next part of the thesis. CpG DNA 
nanotubes were able to induce phenotypically altered macrophages with high TLR 9 
expression in an ischemia-reperfusion (I/R) model. Furthermore, CpG nanoconstructs 
attenuated leukocyte recruitment. However, plain DNA nanotubes promoted the 
invasion of leukocytes into the postischemic tissue without causing increased 
expression of TLR 9 in macrophages. 
In the final part of the thesis, the ability of DNA nanotubes to deliver anti-inflammatory 
drugs was tested. Therefore, the effects and the localization of dexamethasone-
conjugated DNA nanotubes (Dex nanotubes) were examined in vitro as well as in the 
I/R model. The anti-inflammatory molecule dexamethasone could be delivered 
efficiently to target cells using the DNA carrier system in vitro and in vivo. The 
pretreatment with Dex nanotubes in a septic in vitro model significantly reduced the 
TNF response by macrophages without affecting the cell viability. Microinjection of 
Dex nanotubes into postischemic mouse cremaster tissue resulted in a significant 
reduction of leukocyte recruitment. Immunohistological stainings revealed that the 
expression of the endothelial adhesion molecules VCAM-1 and ICAM-1 was 
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diminished after injection of Dex nanotubes, contributing to the attenuated leukocyte 
transmigration.  
Taken together, these results demonstrate that DNA nanotubes can be used as a 
biocompatible platform for the delivery of bioactive molecules to target macrophages 
in vivo. 
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1.2 Zusammenfassung 
 
Das Biomolekül Desoxyribonukleinsäure (DNA) ist essentiell für die Entwicklung, 
Funktion und Reproduktion von lebenden Organismen. Darüber hinaus ist DNA 
jedoch auch ein natürliches Polymer, das durch seine einzigartigen Eigenschaften 
zum Ausgangsmaterial für verschiedenste Entwicklungen im physikalischen, 
medizinischen und biologischen Bereich wurde. DNA ist, durch ihre Struktur, ein 
programmierbares, funktionalisierbares und biokompatibles Basismaterial für die 
Herstellung präziser Strukturen im Nanometerbereich. DNA-basierte Nanokonstrukte 
besitzen großes Potential als Trägersysteme für biomedizinische Anwendungen. 
Allerdings ist bis jetzt nur wenig über ihren Einfluss auf biologische Systeme und die 
Verteilung in Zellen und im Gewebe bekannt.  
Mittels der single-stranded tile Methode, mit der sich komplementäre Oligonukleotide 
(ODNs) in Nanometergenauigkeit zu Konstrukten selbstorganisieren, wurden DNA-
Nanoröhren mit verschiedenen Liganden hergestellt. Diese DNA Strukturen wurden 
auf ihre Funktionalität und Verteilung unter physiologischen und pathologischen 
Bedingungen sowohl im murinen Muskelgewebe als auch in kultivierten 
Makrophagen-Zelllinien untersucht. 
Im ersten Teil dieser Arbeit wurden DNA-Nanoröhren als Trägersysteme für die 
gezielte Anwendung an Makrophagen im murinen Skelettmuskel und auf ihr 
Vermögen, eine Immunantwort zu induzieren, untersucht. An diese DNA-Nanoröhren 
waren immunogene, unmethylierte Cytosin-Phosphat-Guanin (CpG) DNA-
Sequenzen konjugiert, die spezifisch für bakterielle DNA sind und vom angeborenen 
Immunsystem der Vertebraten erkannt werden. Die Erkennung der CpG-Sequenzen 
durch den endosomalen Toll-like Rezeptor 9 (TLR 9) in Makrophagen führte nach 
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Inkubation mit CpG-DNA-Nanoröhren zur Freisetzung des proinflammatorischen 
Zytokins Tumornekrosefaktor (TNF), während Inkubation mit unkonjugierten DNA-
Nanoröhren keine signifikante Immunantwort induzierte. Um die immunogene 
Wirkung der CpG-DNA-Nanoröhren auch in vivo zu bestätigen, wurden die 
Konstrukte in den murinen Cremastermuskel mikroinjiziert. Alle Konstrukte wurden 
gleichmäßig von gewebsständigen Makrophagen aufgenommen, allerdings kam es 
nur nach Injektion von CpG-Nanoröhren zur nukleären Translokation des 
proinflammatorischen Transkriptionsfaktors NF-ĸB und zur Rekrutierung von 
Leukozyten an die Injektionsstelle.        
Da DNA-Nanoröhren spezifisch von Gewebsmakrophagen aufgenommen werden 
und durch den Einsatz eines funktionellen CpG-Motivs die Immunantwort von 
Makrophagen und Mastzellen beeinflusst werden konnte, wurden im nächsten Teil 
dieser Arbeit CpG-DNA-Nanoröhren unter sterilen inflammatorischen Bedingungen 
untersucht. Nach Ischämie-Reperfusion (I/R) führten CpG-tragende Konstrukte in 
vivo zu phänotypisch veränderten Makrophagen mit hoher Expression von TLR 9. 
Darüber hinaus konnten inhibierende Effekte von CpG-Nanokonstrukten auf die 
Leukozytenrekrutierung nachgewiesen werden. Unkonjugierte DNA Nanoröhren 
förderten hingegen die Einwanderung von Leukozyten ins Gewebe, jedoch ohne eine 
erhöhte Expression von TLR 9 in Makrophagen hervorzurufen.  
Im abschließenden Teil dieser Arbeit wurde die Möglichkeit des Transports von 
antiinflammatorischen Wirkstoffen durch DNA-Nanoröhren untersucht. Hierfür 
wurden Dexamethason-konjugierte DNA-Nanoröhren (Dex-Nanoröhren) in vitro als 
auch in vivo im I/R-Modell auf ihre Wirkung und Lokalisation untersucht. Durch das 
DNA-Trägersystem konnte das entzündungshemmende Molekül Dexamethason 
nicht nur in vitro, sondern auch in vivo, sehr effizient aufgenommen werden. Im 
septischen in vitro Modell führte die Vorbehandlung mit Dex-Nanoröhren zu einer 
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reduzierten TNF  Antwort durch Makrophagen ohne Einschränkung der Zellvitalität. 
Die Mikroinjektion von Dex-Nanoröhren in das postischämische, murine Cremaster-
Gewebe hatte eine signifikante Reduktion der Leukozytenrekrutierung zur Folge. 
Immunhistologische Färbungen zeigten, dass die Expression der endothelialen 
Adhäsionsmoleküle VCAM-1 und ICAM-1 durch Injektion von Dex-Nanoröhren 
reduziert wird, was zur geringeren Anzahl an transmigrierten Leukozyten beiträgt.  
Diese Ergebnisse zeigen, dass sich DNA-Nanoröhren als biokompatible 
Nanoplattformen für den Transport von bioaktiven Molekülen in Makrophagen in vivo 
eignen und damit ein besonderes therapeutisches Potential besitzen.    
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2.1 Nanotechnology 
 
The term nanotechnology is referring to the production, manipulation, and use of 
materials at dimensions ranging from 1 to 100 nanometers. The prefix “nano-“ 
derives from the Greek “nanos” (dwarf) and describes the billionth part (=10-9) of 
something. At this scale, materials gain new physical, chemical, and biological 
properties that are not shared with non-nanoscale materials with identical chemical 
composition. The total surface of nanoparticles (NPs) is, compared to the total 
volume, much larger; therefore, the “reactive” surface is also larger. Furthermore, 
NPs show a higher conductivity, higher stability, and a lower melting temperature 
than their larger counterparts. Due to these unique properties, NPs are used in a 
wide variety of applications such as cosmetics, sunscreen [1], water purification 
systems [2], and sensors [3]. NPs are entering areas of our daily lives and also the 
biomedical field. Several classes of engineered NPs are currently applied as 
nanovaccines [4], nanodrugs [5], or diagnostic imaging tools [6]. 
 
2.2 Biological and medical applications of NPs 
 
However, the knowledge about the fate and the biological effects of NPs in vivo has 
not kept up with the pace of these developments. Since NPs have a higher free 
surface energy than the bulk material, the reactivity of nanomaterials with 
biomolecules such as proteins or lipids in body fluids is enhanced [7]. As a result, the 
surface is coated with these molecules. This “biomolecular corona” is in many cases 
interacting with the NPs´ biological environment and therefore crucially determines 
the biological features of NPs [8]. For instance, lipoprotein-coated NPs can passively 
penetrate the cell membrane or attach to it [9], whereas surface ligands such as 
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proteins are recognized by different cellular receptors that trigger internalization and 
cellular activation [10].  
Also size and solubility affect the interaction of NPs with cells and, particularly, cell-
specific parameters such as cell cycle stadium or cell type [11]. The impact of the 
same NP on different cell populations differs significantly and cannot be assumed for 
other cell populations. For potential biomedical applications it is therefore important to 
gain as much knowledge about the impact of certain NP parameters as possible, to 
draw a general conclusion, and to consider the risks. 
The modification of physicochemical properties (such as charge, functional groups, 
size, and shape) of nanomaterials allows the control of distinct cellular uptake and 
immunogenicity, factors that influence the distribution and clearance of these 
particles [12]. To assure the correlation of a particular cellular response to a certain 
NP or property of a NP, it is of great importance to produce precisely defined 
structures and to control their properties. A material which allows the determination of 
many of these properties, because of its high programmability, is DNA. 
 
2.3 DNA nanotechnology 
 
DNA is a central information carrier in biological systems, such as prokaryotic cells, 
eukaryotic cells, bacteriophages, and viruses. The genetic information is encoded in 
nucleic acid sequences, which are complementary Watson-Crick base pairings (Fig. 
1D). Aside from the biological importance, DNA can be assembled into nanometer-
scaled, structurally precise architectures due to its molecular programmability and 
selective hybridization (Fig. 1F) [13]. In 1982, Nadrian Seeman was the first 
considering DNA as molecular building material in a non-biological context [14] and 
he paved the way for structural DNA nanotechnology. From immobile branched 
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junctions in 1983 [15] to complex three-dimensional structures (Fig. 1G) [16, 17] 
nowadays, DNA nanotechnology experienced a rapid development.  
One of the most important advances made during this development was the use of 
scaffold DNA strands for creating desired nanoscale shapes [18]. This new 
technique, called “DNA origami”, was implemented by the group of Paul Rothemund. 
Analog to the Japanese art of paper folding, Rothemund et al. folded a scaffold DNA 
strand, consisting of 7249 nucleotides (nt) derived from the bacteriophage M13, into 
shape with hundreds of shorter oligonucleotides (staple strands) [18]. This method 
now also allows the formation of larger assemblies by multimerizing single DNA 
origami constructs as well as building three-dimensional objects by stacking sheets of 
parallel helices. In this process, staple strands of the inner helix form crossovers with 
staple strands from three neighboring helices [19]. With a reaction yield of about 
90%, DNA origami is a simple and fast method to design and create DNA constructs 
with about 100 nm in diameter (Fig. 1G). Moreover, it serves as a platform for the 
arrangement of heteroelements such as proteins [20-22], NPs [23-25], or carbon 
nanotubes [26] due to the sequence specificity and spatial addressability of DNA 
nanoconstructs. The pattern of components on top of the nanoconstruct can be 
quickly and inexpensively reconfigured to perform a different task [27]. Another 
important feature in the context of biological applications is the stability of DNA 
origami architectures in cell lysates [28]. Two- and three-dimensional 
nanoarchitectures assembled by this technique have been deployed in various 
applications such as single molecule imaging [29], molecular robotics [30], single 
molecule chemistry [31], or immunostimulation [32]. However, due to the scaffold 
strand needed, the DNA origami technique is limited in size, complexity, and large 
scale production.  
  
Fig. 1 Design of DNA nanodevices
DNA nanodevices (A). Small circular, double
genetic engineering in therapeutic and biomedical applications (
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sequences and are used for the molecular recognition of l
conjugates are composed of oriented DNA 
inorganic NP (brown). These constructs have 
genes in vitro and in vivo (E). The
assembly of DNA into polyhedral structures
based construct with controllable lid for the delivery of molecular payloads (
permission from Macmillan Publishers Ltd: Nature 
 
 
A new approach that circumvents the
et al. [34]. The single-stranded tile assembly allows 
striking speed. In this system
domains that specify which four other tiles can bind to it.
position and self-assembles
of tiles is mixed together 
domains remain which can lead to aggregation. To seal the edges, edge protector 
strands are added. Wei et al. drastical
efficient, modular, and robust method, without producing misfolded by
using a robot to select and mix strands, the authors brought DNA nanotechnology 
into a rapid prototyping age 
thousand strands will generate
of a scaffold strand in the future.
The spectrum of strategies to create DNA nanoconstructs is broad, but DNA tile 
assembly and DNA origami are the most popular approaches in DNA 
nanotechnology.   
12 
. The double helix structure of DNA is the basis for many 
-stranded DNA plasmids are used as vectors for 
B). To enhance the efficiency 
with cationic lipids or polyethylenglycol (green) (
G-quadruplexes, are made up
igands (D). Spherical DNA 
ODN strands (green) that are packed on an 
been successfully used for the regulation of 
 sticky-end association of single tiles (top) allows the
 (bottom) (F). A three-dimensional DNA origami
nanotechnology [33] copyright 
se limitations was recently implemented by Wei 
building arbitrary structures with 
, each tile is a single strand with four different binding 
 Each tile adopts a specific 
 to an arbitrary DNA shape, when an appropriate subset 
(Fig. 6). On the edges of each construct
ly reduced the manufacturing time with this 
[27]. It is conceivable that approaches with several
 several kDa huge complex structure
 
2 Introduction 
 
C). 
 of guanine-rich 
NP 
 self-
-
G). Reprinted by 
2015.  
, free binding 
-products. By 
 
s, without the use 
2 Introduction 
 
13 
 
2.4 DNA nanostructures as drug delivery vehicles 
 
DNA nanoconstructs have caught the interest of the drug delivery community, since 
the drug cargo can either be attached to the precisely programmed DNA scaffold or 
enclosed in a three-dimensional structure with targeting ligands attached. Another 
important benefit for the use of DNA structures as drug delivery tools is: they have 
been shown to be non-cytotoxic [32, 35]. Furthermore, the stoichiometry can be fully 
controlled [18, 19] and they survive in cell media, blood serum, and cultured cells for 
extended periods of time [28, 36, 37]. The stability of DNA constructs towards 
nucleases can be significantly enhanced by functionalization, e.g., hexanediol [38] or 
structural compaction.  
Douglas et al. created a DNA nanorobot capable of transporting a molecular payload 
to certain cell subsets under the control of a logic gate [35]. Another powerful 
implementation is the DNA “nano-claw” which autonomously analyzes multiple 
molecular cancer cell signatures and, in response, releases target-specific agents 
[39]. Although there are many sophisticated DNA architectures designed and 
realized, only a few have been applied to complex biological systems like tissue. 
Therefore, a rather simple tube design could be more controllable in vivo and may 
allow a general prediction of the bioactivity of DNA structures in contrast to complex 
multifunctional DNA architectures. To transport drugs efficiently, not only towards the 
target cells but additionally into target cells, is one of the challenges DNA 
nanotechnology needs to face. A promising concept is the functionalization of 
constructs with receptor ligands as guiding or targeting agents. For instance, the 
conjugation of folate to DNA tubes induced their efficient internalization by folate 
receptor-bearing cancer cells [40]. But also size is a vital criterion for cellular uptake. 
Uptake studies with polycation-DNA gene delivery systems (DNA complexed with 
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polycations) revealed that a size below 100 nm promotes maximal endocytosis by 
non-specialized cells [41]. Most uptake mechanisms, e.g., clathrin-mediated 
endocytosis, are receptor-mediated cellular processes. As the size increases, it 
becomes less likely that receptor binding will occur. However, professional 
phagocytes such as macrophages, polymorphonuclear granulocytes, or dendritic 
cells (DCs) are able to internalize objects larger than 500 nm. This requires the 
recognition of the target by specialized surface receptors (e.g., scavenger receptors) 
and subsequent actin rearrangement [42, 43]. For the phagocytosis of particles, an 
actin-dependent extension of the plasma membrane is necessary [44]. The cargo 
size affects not only uptake pathways but also cytotoxicity and biodistribution.  
Negatively charged DNA nanoconstructs are considered to be less toxic than 
positively charged ones, which have a high affinity to the negatively charged cell 
membrane and therefore disrupt the membrane integrity [45].  
As explained above, successful cellular delivery is substantially driven either by 
multiple factors regarding the nanoconstruct such as surface charge, size, and shape 
or by the microenvironment the construct is operating in. The cellular availability of 
the carrier system is strongly dependent on the biological borders (e.g., blood tissue 
border, blood brain barrier, or gut mucosa) that need to be crossed. Therefore, critical 
factors such as construct stability and the delivery across physiologic barriers should 
be regarded. Acid-catalyzed depurination of DNA at low pH and high concentrations 
of deoxyribonucleases (DNases) aggravate the crossing of constructs from the blood 
into the tissue. To mitigate this, direct application into the target tissue is a convenient 
way to circumvent fast degradation by DNase I, since the concentration of DNase I is 
in most murine organs significantly lower than in the blood [46]. Microinjection of DNA 
NPs into the eye [47] and the brain [48] were successful attempts to avoid 
degradation and to facilitate the transfection of target cells such as neurons and glial 
2 Introduction 
 
15 
 
cells. Another interesting target for the administration of functional DNA 
nanoconstructs are macrophages which are essential components of many types of 
tissue and contribute to a wide range of pathologies, such as cancer, arthritis, and 
atherosclerosis [49]. 
 
2.5 Monocytes and macrophages 
 
Macrophages have first been described as phagocytic active cells by Ilya Metchnikoff 
in the 19th century [50]. They are a heterogeneous group of immune cells that are 
essentially distributed in all tissues and capable of altering their phenotype in order to 
suit the microenvironment in which they reside. Macrophages are vital participants in 
the innate and adaptive immune system. Because of multifaceted activities, e.g., the 
removal of invading pathogens, apoptotic cells, and cellular debris, resolution of 
inflammation [51], release of cytokines and growth factors, presentation of antigens 
to T-cells [52], remodeling of matrix components [52, 53], and processing of iron [54], 
macrophages have been identified as key players in diseases with major influence for 
the public health. Cancer, autoimmune, chronic inflammatory, degenerative, and 
metabolic diseases are just a few examples [49]. 
2.5.1 Monocytes 
 
Blood monocytes are derived from hematopoietic stem cells in the bone marrow and 
are present in blood and spleen [55]. They consist of two subtypes – inflammatory 
CCR2hi CX3CR1low Ly6chi monocytes and resident CCR2low CX3CR1hi Ly6clow 
monocytes [56]. While Ly6clow monocytes stay in the blood and patrol along vessel 
walls, Ly6chi monocytes are not only found in the blood but also in tissues such as 
skin, lung, lymph nodes, and spleen [57, 58]. There they control the extravascular 
2 Introduction 
 
16 
 
environment or transport antigens to lymph nodes and support antigen presentation 
[57]. Monocytes do not proliferate in a steady state [55, 59], but mature under certain 
challenges, such as inflammation [60] or atherosclerosis [61] to DCs or macrophages 
in infiltrated tissues [62, 63]. Since macrophage-colony stimulating factor (M-CSF)-
deficient mice show diminished numbers of blood monocytes [64], it has been 
demonstrated that interleukin-34 (IL-34) and M-CSF strongly push the development 
of this lineage [60, 65]. 
2.5.2 Tissue-resident macrophages 
 
Although it has long been the prevailing view that tissue macrophages originate from 
adult blood monocytes, recent publications revealed that most lineages of tissue 
macrophages are established during embryonic development from the yolk sac, the 
fetal liver, or the bone marrow [66-70]. The various sources of development 
distinguish monocytes from tissue macrophages, which have a limited ability to 
migrate. Tissue macrophages are extremely heterogeneous in phenotype, 
homeostatic turnover, and function, thus they are well adapted to the anatomical 
locations they reside (Fig. 2) [71, 72]. This adaptation also manifests in tissue-
specific transcription and epigenetic programs [73, 74]. Bone macrophages, so-called 
osteoclasts, are specialized in the resorption of bone. This process is associated with 
a high expression of carbonic anhydrase II [75] in osteoclasts which is known to be 
important for the acidic degradation of bone material. Another example are microglia, 
macrophages in the brain. They produce brain-derived neurotrophic factor (BDNF) 
which is a key modulator of neuronal synaptic plasticity and the formation of memory 
[76]. Dysfunctions or abnormalities of tissue-resident macrophages in turn lead to a 
variety of diseases. For instance, osteopetrosis results in insufficient bone resorption 
due to a defectiv osteoclast development [77]. 
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Furthermore, tissue-resident macrophages are able to dynamically change their 
activation status and phenotype in response to their environment [78]. The 
reprogramming of the epigenetic program changes the phenotype of macrophages. 
Lavin et al. transferred macrophages originating from the peritoneum into the lung 
and, as a result, the majority of macrophages acquired the gene expression profile of 
lung macrophages [78]. This study demonstrated that tissue-resident macrophages 
exhibit a phenotypic plasticity and polarization, occurring during inflammation, which 
is reversible. These characteristics together with their prominent role in mammalian 
tissues nominate them as attractive therapeutic targets. 
 
 
Fig. 2 Tissue-resident macrophages in the cremaster muscle. Confocal imaging of tissue-
resident macrophages 60 min after intrascrotal injection of carboxyl quantum dot (cQD) NPs. 
F4/80-positive tissue-resident macrophages (red) phagocytose cQDs (blue) after application 
into the murine cremaster muscle. These F4/80-positive tissue-resident macrophages line 
the interstitial tissue between muscle fibers (phalloidin, green). Scale bar: 20 µm.  
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2.5.3 Activation and polarization of macrophages 
  
Macrophages bridge the two categories of immunity: the innate and the adaptive 
immune system. The innate immune system detects and responds to various 
pathogens via a broad range of pattern-recognition receptors, e.g., TLRs and NOD-
like receptors (NLRs). These enable them to sense common structural and functional 
features associated with different classes of microorganisms, foreign substances, or 
cellular components [79]. Thus, the expression pattern of these receptors is highly 
dependent on the microenvironment. Subsequent to the encounter of pathogens, 
receptor activation is translated into different classes of effector responses such as 
phagocytosis, inflammasome formation [80], and cytokine production.   
On the one hand, cytokines can amplify the immune response and on the other hand 
they directly impact the transmigratory activity of inflammatory leukocytes, largely 
neutrophils and monocytes, from the blood stream into the affected tissue [81]. Once 
activated, inflammatory macrophages present the processed antigens via the major 
histocompatibility complex II (MHC II) to lymphocytes such as T-cells [82]. 
Subsequently, these T-cells can stimulate B-cells to generate antibodies, specific to 
the presented antigen, which leads to immediate and long-lasting defense against a 
specific pathogen.  
Monocyte-derived macrophages populate the inflammatory foci, proliferate, and 
make up the majority of present macrophages. Fundamental for proliferation of all 
subpopulations, under physiologic and pathologic conditions, is the growth factor M-
CSF [72, 83]. In contrast to monocyte-derived macrophages, resident macrophages 
though having the ability to proliferate, the proliferation is tightly regulated and 
dampened once normal tissue numbers are obtained [83, 84]. However their 
importance is stated by the observation that the depletion of resident macrophages 
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with chlodronate liposomes leads to an altered immune response due to the absence 
of inflammatory mediators, such as chemokines, cytokines, lipid mediators, and a 
disrupted host defense [85-87].  
In general, macrophages actively scan their microenvironment and certain stimuli 
polarize the cells into another phenotypic and functional subpopulation. The “M1-M2 
paradigm” describes two well-studied macrophage subsets established according to 
their gene expression profiles and their functional activities [88]. M1 macrophages 
promote host defense and antitumor immunity via the production of reactive oxygen 
and nitrogen species and pro-inflammatory cytokines (TNF, IL-12, and IL-1β) [89]. 
Alternatively activated macrophages (M2 macrophages) facilitate wound repair, 
regulate glucose metabolism, suppress inflammation and antitumor immunity [90]. 
“Regulatory macrophages” are a third population, which are generated in the 
presence of TLR agonists and Immunoglobulin G (IgG) complexes [91]. Other factors 
turning the macrophage development into a regulatory direction are IL-10 [92], 
apoptotic cells [93], or prostaglandins [94]. Due to the production of the 
immunosuppressive cytokines IL-10 and TGF-β, these cells have the propensity to 
induce an anti-inflammatory TH2 and regulatory T-cell response to dampen chronic 
inflammatory and antitumor responses.   
 
2.6 Leukocyte recruitment from the microcirculation 
 
Leukocytes, also called white blood cells, are a group of immune cells that fulfill 
specific effector functions within the immune defense in lymphoid and peripheral 
tissue. Leukocytes can be classified in two major lineages: the myeloid lineage 
including neutrophils, eosinophils, basophils, and monocytes, and the lymphoid 
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lineage including B-cells, T-cells, and natural killer cells [95]. They are generated 
from hematopoietic stem cells in the bone marrow and circulate through the blood 
and the lymphatic system. In order to eliminate invading microorganisms or in the 
incidence of a sterile tissue injury, leukocytes extravasate the bloodstream from 
postcapillary venules into the interstitial space. The recruitment of leukocytes into 
inflamed tissue is considered to be a fundamental part of inflammatory processes, 
however leukocytes are also required to support repair mechanisms of the tissue.  
The current model of leukocyte recruitment is described by a well-defined series of 
steps termed the leukocyte-adhesion cascade. The interactions, occurring between 
blood-borne leukocytes and endothelial cells (ECs), are characterized by capture and 
rolling of leukocytes at the endothelium and firm adhesion to ECs. Next, leukocytes 
start to crawl on the luminal site and transmigrate through the vessel wall. Upon their 
arrival at the abluminal site of the vessel, leukocytes exhibit movements along 
pericyte processes, then breach the pericyte layer, and finally detach from the vessel 
wall to migrate towards an inflammatory focus [96].  
These serial steps are initiated by the release of pathogen-associated molecular 
patterns (PAMPs) from invading microorganisms or damage-associated molecular 
patterns (DAMPs) released from damaged or dead cells. The perception of PAMPs or 
DAMPs is mediated by a heterogeneous group of pattern recognition receptors, such 
as TLRs, NLRs, or C-type lectin receptors (CLRs). These receptors can be 
expressed intracellularly or on the surface of tissue-resident sentinel cells, such as 
macrophages, mast cells, or DCs. These cells respond to the danger signals by 
releasing chemokines (e.g., CXCL-1, CXCL-8), cytokines (e.g., IL-1, IL-6, TNF), or 
chemoattractants (e.g., LTB4, PAF). Proinflammatory mediators, such as IL-1 and 
TNF, activate ECs to express adhesion molecules (selectins, integrins, VCAM-1, and 
ICAM-1) which facilitate the different steps of leukocyte transmigration. Subsequently, 
  
the gradients of soluble or surface
leukocytes to the injury, where they remove dead cells and promote tissue repair
(Fig. 3). Hence, leukocytes strongly contribute to tissue homeostasis. Since leukocyte 
migration is fundamental for adequate immune response, deficiencies in this process 
can have drastic consequences. 
bacterial and fungal infections
contribute to a multitude of prominent diseases such as rheumatoid arthritis, Crohn
disease, multiple sclerosis,
the challenge that novel therapeutic approaches for inflammatory diseases need to 
face.  
 
Fig. 3 Leukocyte recruitment
inflammatory response in tissue
leads to the generation and release of chemoattractants 
blood stream. Leukocytes follow a multistep adhesion cascade, starting with rolling on the 
endothelium, adherence, and finally transmigration into the interstitial space. During this 
series of steps they follow the chemotactic gradient
phagocytose pathogens and cellular debris. Figure adapted and modified 
al. 2014. Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews 
Immunology [81] copyright 2014.
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2.7 Ischemia-reperfusion injury 
 
Ischemic heart disease is the leading cause of death in developed countries [98]. 
After an initial restriction of blood supply, classically induced by an embolus, the 
imbalanced metabolic tissue supply causes tissue hypoxia. The subsequent 
restoration of reperfusion and reoxygenation is responsible for exacerbated tissue 
injury and inflammation [99]. The mortality of ischemic heart diseases is often related 
to microvascular dysfunction, enhanced vascular permeability, and the recruitment of 
leukocytes from postcapillary venules [100]. The detrimental effects of I/R injury 
result from the induction of cell death programs such as apoptosis and necrosis. 
Although I/R injury induces a sterile environment, innate immunological mechanisms, 
such as complement activation and adaptive mechanisms, are contributing to severe 
tissue damage [101].  
Leukocytes are key modulators of I/R injury since they are the source of 
proinflammatory cytokines, reactive oxygen species, and proteases, which are able 
to enhance the postischemic tissue damage [102]. On the other hand, leukocytes 
support the regeneration and the healing of postischemic tissue, e.g., by maintaining 
tissue homeostasis by phagocytosis of apoptotic cells [103, 104]. Tissue 
macrophages are contributing to a proinflammatory milieu through the release of 
soluble proinflammatory mediators, e.g., TNF. These mediators stimulate ECs to 
upregulate adhesion molecules that facilitate rolling, capture, and transmigration of 
leukocytes. Leukocyte-endothelial cell adhesion and platelet-leukocyte aggregation 
aggravate microvascular dysfunction [105]. 
The activation of macrophages and other immune cells in an inflamed environment is 
partly mediated through pattern-recognition receptors such as TLRs. Although the I/R 
injury occurs in a sterile environment, the consequence of I/R is phenotypically 
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similar to the immune response towards invading pathogens. Recent studies have 
implicated TLR signaling in various ischemic diseases, e.g., inhibition of TLR 4 
signaling protected the myocardium from I/R injury [106] and preconditioning with 
TLR 2, TLR 3, TLR 4, TLR 7 and TLR 9 ligands induced ischemic tolerance and 
reduced cerebral ischemic damage [107-111].  
 
2.8 Toll-like receptor 9 
 
So far, 10 functional TLRs have been identified in the mouse and are largely divided 
into two subgroups depending on their cellular localization and respective PAMP 
ligands. One group is expressed on the cell surface and the other group, composed 
of TLR 3, TLR 7, TLR 8, and TLR 9, are expressed in intracellular vesicles such as 
the endoplasmic reticulum (ER), endosomes, lysosomes, and endolysosomes, where 
they recognize microbial nucleic acids [112].  
The ligands of the endosomal TLR 9, unmethylated CpG-DNA from bacteria and 
DNA-containing immune complexes from necrotic cells [113, 114], activate the 
myeloid differentiation primary response gene 88 (MyD88)-dependent NF-κB 
signaling (Fig. 4) as well as PI3K/Akt signaling which improves cell survival [115]. 
Unmethylated CpG ODNs have immunogenic properties and therefore hold great 
promise for therapeutic applications in a wide range of TLR 9-dependent pathologies, 
such as tumor-mediated immunosuppression, allergies, or asthma [111, 112]. 
 
  
Fig. 4 TLR 9 signaling in tissue
resident macrophages phagocytose CpG DNA from the extracellular space
acidic endolysosomal compartments. The lysosome contains TLR
DNA and as a result, induce
activates MYD88 followed by the activation of the IRAK
made of IKKα, IKKβ, and IKK
complex by TRAF6 results in the degradation of I
cytoplasm into the nucleus, where it facilitates the expression of inflammatory cytokines such 
as TNF. 
 
Asthma or allergic reactions are dominated by a T
promotes IgE production and eosinophilic response. The redirection of this T
response in favor of a TH1 response is achieved by the application of CpG DNA. 
Otherwise, CpG DNA can even act beneficial in a sterile inflammation, for example 
during cerebral ischemia [116
DNA increased TNF levels
stroke [110]. 
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2.9 Aim of the study 
 
As explained above, DNA-based nanostructures are gaining importance in biological 
and biomedical research since they can be modified with a plethora of (bio)chemical 
moieties with nanoscale precision and full control over stoichiometry. Particularly, the 
nanoscale programmability and ease of fabrication of DNA-based nanostructures 
have sparked interest. However, the in vivo behavior of such constructs at the 
microscopic tissue/cell level as well as their inflammatory potential are largely 
unknown. 
The aim of this work was to investigate the potential of DNA nanoconstructs as 
innovative platform for the efficient and biocompatible delivery of drugs in vivo to 
macrophages, which are key players in homeostasis, immune defense, and disease. 
For this purpose, immunostimulatory CpG ODNs or immunosuppressive 
dexamethasone were conjugated to DNA nanotubes. In in vitro experiments, the 
uptake efficiency and the impact on cellular cytokine production in macrophage cell 
lines were studied. In further in vivo experiments, the local distribution, the bioactivity, 
and the effects of these DNA constructs on leukocyte recruitment were investigated 
under physiological and pathological conditions (I/R) in the murine cremaster muscle. 
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3.1 Material 
All used consumables are listed in the Appendix.  
 
3.2 Methods  
3.2.1 Design and assembly of DNA nanotubes 
 
DNA nanotube design, assembly, and characterization were mainly done by Samet 
Kocabey and Tim Liedl (Department of Physics, LMU) in close cooperation and with 
conceptual input from the author of this thesis. For the sake of completeness and to 
deepen the understanding of DNA nanotubes the design, assembly and 
characterization of DNA nanotubes are included in this thesis. 
 
3.2.1.1 Design of 8-helix DNA nanotubes 
 
DNA nanotubes were designed using the single-stranded tile (SST) method, where 
each tile oligonucleotide is 42 bases long and consists of four domains with 10 or 11 
bases. Each domain is complementary to one domain on the neighboring tile [34, 
117]. We designed 8-helix tubes consisting of 48 individual tile ODNs folding into 8 
parallel double helices. Tile strands located at the ends of the tube contain non-
pairing poly-A sequences in order to prevent sticky end formation and polymerization. 
For CpG labeling, the 3´ ends of 24 tiles (every second tile in each helix) were 
extended by 20 bases containing the immune stimulatory CpG motif, GACGTT, twice 
(CpG 1826: TCCATGACGTTCCTGACGTT). For control tubes, that do not carry the 
CpG motif, tiles without CpG extension were used. All ODNs were purchased from 
Eurofins Operon MWG (Ebersberg, Germany) with HPSF purification. 
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3.2.1.2 Design of 6-helix DNA nanotubes 
 
DNA nanotubes were designed using SST, where each SST ODN has 21 base long 
domains complementary to the adjacent domains on the neighboring tiles. 15 
individual SST were used to fold 6-helix nanotubes. The domains at the end of the 
nanotube contain non-pairing poly-A sequences to prevent polymerization. To 
generate a pH-responsive DNA nanoconstruct, 3 of the tiles were extended with an i-
motif sequence (CCCTAACCCTAACCCTAACCC) facilitating the release of 
dexamethasone handles at acidic pH. For dexamethasone conjugation, 3 of the tile 
ODNs extended with the i-motif sequence or a random sequence were hybridized 
with dexamethasone-conjugated single-stranded ODNs. All unmodified ODNs (HPSF 
purified) and amine-modified ODNs (HPLC purified) were purchased from Eurofins 
Operon MWG (Ebersberg, Germany) (see the Supporting Information, Table S1 for 
the sequences).  
 
3.2.1.3 Dexamethasone conjugation 
 
Amine-modified single-stranded ODNs were conjugated with dexamethasone using 
the method developed by Acedo et al. [118]. In brief, dexamethasone (0.4 g, 1 mmol, 
Sigma) was reacted with succinic anhydride (0.15 g, 1.5 mmol) and DMAP (0.13 g, 1 
mmol) in pyridine at room temperature for 20 h. The reaction mixture was 
concentrated by drying in vacuum evaporator, then re-dissolved in 150 ml of 
DCM/MeOH (4:1), and washed twice with 75 ml of 1 M sulfuric acid and water. The 
organic white solid formed after the reaction, dexamethasone succinic acid (0.25 g, 
0.5 mmol), was reacted with N-hydroxysuccinimide (70 mg, 0.6 mmol) and DCC (125 
mg, 0.6 mmol) in 5 ml of THF at room temperature for 20 h. After several filtration 
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and washing steps, the final residue was dissolved in 5 ml DMF (10 mM) and stored 
at 4 °C for months. For DNA coupling, 10 µl of 5´amine-labeled ODN (100 µM) and 
10 µl of dexamethasone-NHS (10 mM) were mixed in Tris buffer (50 mM, pH 7.4) 
and incubated at room temperature overnight. On the next day, the solution was 
centrifuged at 13000 g for 5 min and supernatant was collected. The solution was 
evaporated to remove DMF in a vacuum centrifuge and redissolved in water. The 
centrifugation and evaporation steps were repeated several times. Finally, 
dexamethasone-conjugated ODNs (Dex ODNs) were purified using 3 K Amicon Ultra 
0.5 ml centrifuge filters for further use in dye labeling and assembly.   
 
3.2.1.4 Enzymatic dye labeling of tiles  
 
To visualize the DNA nanotubes in vivo, the 3´ ends of some of the tile strands were 
enzymatically labeled with Atto488-dUTP or Atto546-dUTP [119]. For Dex nanotubes 
6 of the tiles at the middle part of the structure and Dex ODNs were enzymatically 
labeled with Atto488-dUTP and Atto647N-dUTP respectively. Further, Atto-dUTPs 
(80 µM, purchased from Jena Bioscience, Jena, Germany), CoCl2 (5 mM), terminal 
transferase enzyme (16 U/µl, Roche, Penzberg, Germany), and all DNA tiles (400 
pmol) were mixed in 20 µl 1x TdT reaction buffer. The solution was incubated at 37 
°C for 60 min. Then, 2.5 µl of NaOAc (3 M) was added and the solution was filled up 
to 80 µl with ice-cooled ethanol (99 %). After 1 h of incubation at -20 °C, samples 
were centrifuged at 13000 g for 30 min. Then, samples were washed with 70 % 
ethanol for 10 min again and the supernatant was discarded. The remaining pellet 
was re-dissolved in distilled water. For CpG-labeled tubes, 24 of the unmodified tiles 
and for the control tubes, 40 of the core tiles were used for dye labeling. For CpG 
ODNs, 24 of the tiles with CpG sequence were labeled with dye. 
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3.2.1.5 DNA nanotube assembly and purification 
 
For the annealing of DNA nanotubes, 800 nM (8-helix tubes) or 1µM (6-helix tubes) 
of each tile (dye-modified and unmodified) were mixed with folding buffer (10 mM 
Tris-HCl, 1 mM EDTA, pH 8.0, 20 mM MgCl2). The DNA nanotubes were folded over 
the course of 16 h (5 min at 80 °C, cooling down to 65 °C at 1 °C/min, cooling down 
to 25 °C at 2.5 °C/h). The assembled 8-helix nanotubes (CpG nanoconstructs) were 
then purified using 30 K Amicon Ultra 0.5 ml centrifuge filters (30000 MWCO, 
Millipore, Schwalbach, Germany) in order to remove excess strands that were not 
folded into the structures. For 8-helix nanotube (Dex nanotubes) purification, 100 K 
Amicon Ultra 0.5 ml centrifuge filters (100000 MWCO, Millipore, Schwalbach, 
Germany) were used. 100 µl of assembled DNA tube solution was completed up to 
500 µl with folding buffer, filled into the centrifuge filter, and centrifuged 3 times at 
13000 g for 6 min. After every centrifugation step, the flow-through was removed and 
the filter was refilled up to 500 µl with buffer. After final centrifugation, the remaining 
solution at the bottom of the filter (~ 50 µl) was pipetted out and the concentration of 
tubes was determined by measuring the optical density at 260 nm. Overall, 50 – 60 
% of the initial amount of DNA nanotubes was obtained after purification. 
 
3.2.1.6 Gel electrophoresis and transmission electron microscopy  
 
To analyze DNA nanotubes, the samples were run in an agarose gel. 2 % agarose 
was dissolved in 0.5 x TBE buffer by heating to boiling. After cooling, MgCl2 was 
added to 11 mM final concentration and the solution was poured into a gel cask for 
solidification. 10 µl of each filter-purified DNA tube sample were mixed with 2 µl of 6x 
loading dye before loading into the gel pockets. 6 µl of 1 kb ladder was also loaded 
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adjacent to the samples. The gel was run for 2 h at 70 V in an ice-cooled water bath 
to prevent heat-induced denaturation of DNA nanotubes. After running, the gel was 
stained with ethidium bromide (0.5 µg/ml) for 30 min. 
DNA nanotubes were visualized by electron microscopy using a JEM-1011 (JEOL, 
Freising, Germany) transmission electron microscope (TEM). The DNA nanotubes 
were incubated on plasma-exposed (240 kV for 1 min) carbon-coated grids and then 
negatively stained with 1 % uranyl acetate for 15s. 
 
3.2.1.7 Stability of DNA nanotubes 
 
Stability of DNA nanotubes and pUC 18 double stranded-plasmid were tested in 
DNAse I-containing buffer, mice serum and fetal calf serum (FCS) separately. For 
DNAse I experiments 50 ng/µl of each sample was incubated in buffer at 37 °C for 
different time periods. To emulate in vivo conditions, the DNAse I concentration was 
adjusted to 1.97 U x 10-4 U/g wet weight [46]. For further experiments, mice serum 
was diluted 37 times to mimic conditions prevalent in the skeletal muscle [46]. The 
DNA nanotubes were also incubated in pure FCS (not heat-inactivated) for up to 2 h. 
Zeta potential and size measurements were performed with a Zetasizer Nano 
(Malvern Instruments, Malvern, UK) at 100 nM nanotube concentration. 
 
3.2.1.8 Gel electrophoresis to test the functionality of pH-responsive 
Dex tubes 
 
To test the i-motif-dependent release of single-stranded Dex ODNs, 100 µl of DNA 
nanotubes were filled up with 50 mM MES buffer (pH 5.5) to 500 µl and incubated at 
37 °C for 30 min. Then, the samples were centrifuged 3 times at 13000 g for 6 min 
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using 100 K Amicon filters. The samples were analyzed by running a 2 % agarose 
gel (0.5 x TBE, 11 mM MgCl2) as described in 3.2.1.6. 
 
3.2.2 Cell culture 
3.2.2.1 RAW 264.7 cells 
 
Murine RAW 264.7 macrophage-like cells were purchased from American Type 
Culture Collection (Rockville, USA) and grown in Dulbecco´s modified eagle medium 
(DMEM) supplemented with 10 % FCS, 4 mM L-Glutamin and 1 g/L D-Glucose at 37 
°C and 5 % CO2. For passaging, medium was removed, cells were washed twice with 
phosphate-buffered saline (PBS) and 3 mL of pre-warmed Trypsin-EDTA (0.5 %) was 
added and incubated for 15 min at 37 °C. Digestion was stopped by adding 7 mL pre-
warmed DMEM. After resuspension in culture medium, RAW 264.7 cells were 
collected in falcon tubes and centrifuged (1100 rpm, 5 min, room temperature). Cells 
were resuspended and transferred to a new flask or seeded for experiments. RAW 
264.7 cells were split every 2 to 3 days.   
 
3.2.2.2 Stimulation of RAW 264.7 cells 
 
Cells were seeded on 24-well culture plates at a density of 4 x 105 cells and 
cultivated for 24 h. For stimulation, RAW 264.7 cells were incubated with DNA 
nanotube constructs or CpG ODNs for up to 12 h. Culture supernatants were 
collected and stored at -80 °C for further analysis. Cells were washed and 
resuspended in DMEM, and uptake of DNA constructs and ODNs was visualized 
using a confocal laser-scanning microscope (Leica SP5, Leica Microsystems, 
Wetzlar, Germany) equipped with a GaAsP hybrid detection system (Leica HyD).  
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3.2.2.3 MH-S cells 
 
MH-S, a murine alveolar macrophage cell line was purchased from American Type 
Culture Collection (Rockville, USA). Cells were grown in complete RPMI-1640 
medium supplemented with 10 % FCS and 0.05 mM 2-mercaptoethanol at 37 °C and 
5 % CO2. For passaging, medium was removed, cells were washed twice with PBS, 
and 3 mL of pre-warmed Trypsin-EDTA (0.5 %) was added and incubated for 5 min 
at 37 °C. Digestion was stopped by adding 7 mL pre-warmed RPMI-1640. After 
resuspension in culture medium, MH-S cells were collected in falcon tubes and 
centrifuged (1100 rpm, 5 min, room temperature). Cells were resuspended and 
transferred to a new flask or seeded for experiments. MH-S cells were split every 3 to 
4 days. 
 
3.2.2.4 Flow cytometry 
 
Upon incubation with DNA nanoconstructs, cells were washed with culture medium 
and transferred with 250 µl PBS into BD Falcon round bottom tubes. The 
fluorescence intensity of incorporated Cy3-coupled DNA constructs was determined 
by a Gallios flow cytometer (Beckman Coulter Inc, Brea, USA) in order to quantify the 
uptake of DNA nanoconstructs. Post-acquisition analysis was performed using 
FlowJo software (Tree Star, Ashland, US). 
 
3.2.2.5 Enzyme-linked immunosorbent assay (ELISA) 
 
Cell culture supernatants were collected after treatment with different DNA 
nanoconstructs and stored at -80 °C until analysis. The concentration of TNF in 
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culture supernatants was determined by enzyme-linked immunosorbent assay 
(ELISA) according to the manufacturer´s instructions (R&D Systems, Wiesbaden, 
Germany). Concentrations were calculated with a standard curve. 
 
3.2.2.6 Water-soluble tetrazolium salt (WST) cell viability assay 
 
MH-S cells were seeded into 96-well plates at a density of 1 x 105 cells per well. After 
adding 50 nM of Dex DNA constructs, LPS (10 ng/ml), Ethanol (70 % for 2 min) and 
dexamethasone (40 ng/ml and 1µg/ml) the supernatant was discarded at different 
timepoints (1 h, 3 h, 6 h, and 12 h) and 10 % Roche WST reagent was added to the 
plate. After 15 min of incubation at 37 °C and 5 % CO2 the absorbance at 490 nm 
was determined using an InfiniteF200 microplate reader (Tecan, Männedorf, 
Switzerland). 
 
3.2.3 In vivo imaging  
3.2.3.1 Animals 
 
Male C57BL/6 mice at the age of 10-12 weeks were purchased from Charles River 
(Sulzfeld, Germany) and MacGreen mice (JAX, Stock Number: 018549) were 
obtained from The Jackson Laboratory (Bar Harbor, USA). Male, heterozygous 
CX3CR1-EGFP mice were generated as previously described and backcrossed to the 
C57BL/6 background for six to ten generations [120]. All experiments were performed 
using mice at the age of 10-12 weeks. Animals were housed under conventional 
conditions with free access to food and water. All experiments were performed 
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according to German legislation for the protection of animals and approved by the 
Regierung von Oberbayern, München, Germany. 
 
3.2.3.2 Surgical procedure 
 
The surgical preparation was performed as described by Baez with minor 
modifications [121]. Briefly, mice were anesthetized by i.p. injection of a 
ketamine/xylazine mixture (100 mg/kg ketamine and 10 mg/kg xylazine). The left 
femoral artery was cannulated in a retrograde manner for administration of 2 µm 
FluoSpheres (Invitrogen, Carlsbad, CA, USA) for measurement of blood flow 
velocities. The right cremaster muscle was exposed through a ventral incision of the 
scrotum. The muscle was opened ventrally in a relatively avascular zone, using 
careful electrocautery to stop any bleeding, and spread over the pedestal of a 
custom-made microscopy stage. Epididymis and testicle were detached from the 
cremaster muscle and placed into the abdominal cavity. Throughout the procedure, 
as well as after surgical preparation during in vivo microscopy, the muscle was 
superfused with warm buffered saline. The body temperature was maintained at 37 
°C using a heating pad placed under the mouse. After in vivo microscopy, tissue 
samples of the cremaster muscle were prepared for immunohistochemistry. Blood 
samples were collected by cardiac puncture for the determination of systemic 
leukocyte counts using a Coulter ACT Counter (Coulter Corp., Miami, USA). 
Anaesthetized animals were then euthanized by an intra-arterial pentobarbital 
overdose (Narcoren, Merial, Hallbergmoos, Germany). 
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3.2.3.3 Mouse model of I/R 
 
For the analysis of postischemic cellular responses to DNA constructs, a 
postcapillary venule segment of the cremaster muscle was randomly chosen. After 
having obtained baseline recordings of leukocyte firm adhesion and transmigration in 
the segment, ischemia was induced by clamping all supplying vessels at the base of 
the cremaster muscle using a vascular clamp (Martin, Tuttlingen, Germany). After 30 
min of ischemia, the vascular clamp was removed, reperfusion was restored, and firm 
adhesion and transmigration of leukocytes were recorded again. Immediately after 
removing the vascular clamp, DNA nanoconstructs were microinjected next to the 
vessel and measurements were repeated at 30 min, 60 min, and 90 min after 
injection. Blood flow velocity was determined as described above previously [122]. 
After in vivo microscopy, tissue samples of the cremaster muscle were prepared for 
immunohistochemistry. 
 
 
 
 
 
 
 
Fig. 5 Experimental protocol for the analysis of leukocyte recruitment after ischemia and 
reperfusion  
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3.2.3.4 In vivo microscopy 
 
The setup for in vivo microscopy was centered around a VisiScope.A1 imaging 
system, equipped with an LED light source for fluorescence epi-illumination. For DNA 
nanotubes or ODN excitation the 470 nm or 550 nm LED modules (exposure time 
700 ms), and for transillumination the 655 nm LED module (exposure time 10 ms) 
were used in a fast simultaneous mode. Light was directed onto the specimen via a 
triple dichroic filter NC316973 (z 405/488/561 rpc; Chroma Technology Corp., 
Bellows Falls, USA). Microscopic images were obtained with a water dipping 
objective (20 x, NA 1.0). Light from the specimen was separated with a beam splitter 
(T 580 lpxxr Chroma Technology Corp., Bellows Falls, USA) and acquired with two 
Rolera EM2 cameras and VisiView Imaging software (Visitron Systems GmbH, 
Puchheim, Germany). Oblique transillumination was obtained by positioning a 
mirroring surface (reflector) directly below the specimen and tilting its angle relative to 
the horizontal plane as described previously [123].  
 
3.2.3.5 Microinjection of DNA nanotubes and LysoTracker dye 
 
Local administration of 250 +/- 100 pl of fluorescently labeled DNA nanotubes (500 
nM), CpG DNA nanotubes (500 nM), CpG ODNs (12 µM), or saline into the 
cremaster muscle was performed via perivenular microinjection in regions at a 
distance of 25 to 75 µm from a postcapillary venule. Dex nanotubes (1.5 µM), Dex 
nanotubes w/o imotif (1.5 µM), DNA tubes (1.5 µM), and Dex ODNs (4.5 µM) were 
immediately microinjected after removing the vascular clamp during I/R as previously 
described. Venules with diameters ranging between 25 and 35 µm were selected for 
the experiments. Microinjection was performed under visual control of the intravital 
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microscope, with a long distance air objective (20 x, NA 0.4 Olympus), using 
borosilicate glass micropipettes - pulled with a micropipette puller - which were 
connected to the injection system consisting of a micromanipulator and a 
microinjector. The tip pressure during injection was 3000 hPa and the tip diameter < 
1 µm. The vessel and the surrounding tissue were visualized during a time period of 
1 min at baseline conditions before injection and up to 90 min after injection. For 
LysoTracker Red DND-99 co-microinjection, the stock solution was diluted to a 
concentration of 750 nM in saline and further diluted to an end concentration of 75 
nM in the respective CpG DNA nanotube sample. For LysoTracker Red DND-99 and 
LysoTracker Green DND 26 co-microinjection, the stock solution was diluted to a 
concentration of 750 nM in saline and further diluted to an end concentration of 75 
nM in the respective Dex nanotubes sample. Different fluorescent labels (as 
described above) did not affect the distribution and localization of DNA 
nanoconstructs.  
 
3.2.3.6 Quantification of leukocyte kinetics and microhemodynamic 
parameters 
 
To quantify the sequential steps of leukocyte extravasation, in vivo microscopy 
records were analyzed offline using ImageJ software (National Institutes of Health, 
Bethesda, USA). Firmly adherent cells were determined as those resting in the 
associated blood flow for more than 30 sec and related to the luminal surface per 100 
µm vessel length. Transmigrated cells were counted in regions of interest, covering 
75 µm on both sides of a vessel over 100 µm vessel length, and are presented per 
104 µm2. Green fluorescent beads (FluoSpheres 2 µm, Invitrogen, Carlsbad, USA) 
were injected via the femoral artery catheter and their passage through the vessels of 
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interest was recorded (filter T580lpxxr, LED 470 nm, exposure 50 ms, cycle time 1 
min). Centerline blood flow velocity was determined by measuring the progression of 
free flowing fluorescent beads in subsequent images in the blood stream.  
 
3.2.3.7 Immunostaining 
 
After dissection of the cremaster muscle, the tissue was fixed with 2 % 
paraformaldehyde for 15 min at room temperature, then blocked and permeabilized 
in PBS, supplemented with 2 % bovine serum albumin (BSA) and 0.5 % Triton X-100 
for 1 h at room temperature. This blocking solution was used to dilute primary 
antibodies at 1:100 and the tissue was incubated at 4°C over night with the antibody 
solution. Before incubation with secondary antibodies (1:400 in blocking solution) and 
TO-PRO3®-Iodide (1:1000 in blocking solution) for 2 h at room temperature, the 
tissue was washed twice with PBS for 5 min. After washing, immunostained 
cremaster muscles were mounted in PermaFlourTM Aqueous Mounting Medium on 
glass slides. For localization of microinjected DNA constructs in Csfr1-EGFP mice as 
well as colocalization with LysoTracker dye, the dissected cremaster muscle was 
mounted in a custom-made imaging chamber and was immediately viewed. Images 
were obtained using a Leica SP5 confocal laser-scanning microscope - equipped 
with a Leica HyD GaAsP hybrid detection system - with an oil-immersion lens, as 
previously described [124]. Images were processed with ImageJ software and figures 
were assembled in Photoshop 9 (Adobe Systems, Mountain View, USA). 
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3.2.3.8 CpG DNA nanotubes in vivo 
Experimental groups  
In a first set of experiments, mice (n=6 each group) received saline, DNA nanotubes, 
CpG DNA nanotubes, or CpG ODNs 20 min after the preparation of the cremaster 
muscle via microinjection. Additional experiments were performed in mice (n=6) 
receiving cromolyn (0.2 mg/kg), an inhibitor of mast cell degranulation, as a bolus via 
intra-arterial injection 30 minutes before cremaster preparation and subsequent 
application of CpG DNA nanotubes. The animals were randomly assigned to the 
experimental groups. 
 
3.2.3.9 CpG DNA nanotubes in vivo during I/R injury 
Experimental groups  
Mice (n=6 each group) received saline, DNA nanotubes, CpG DNA nanotubes, or 
CpG ODNs via microinjection into the postischemic cremaster muscle tissue. The 
animals were randomly assigned to the experimental groups. 
 
3.2.3.10 Dex nanotubes in vivo during I/R injury 
Experimental groups  
Mice (n=6 each group) received saline, DNA nanotubes, Dex nanotubes, Dex 
nanotubes w/o i-motif, Dex ODNs, or dexamethasone (1 µg/ml) via microinjection into 
the postischemic cremaster muscle tissue. The animals were randomly assigned to 
the experimental groups. 
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3.2.4 Statistical analysis 
 
GraphPad Prism 6 (GraphPad Software Inc., La Jolla, USA) was used for statistical 
analysis. Groups were compared with one-way ANOVA followed by a multiple 
comparison test (Tukey´s test). In all cases, p values of p<0.05 were considered to 
be significant. 
  
 
 
 
 
 
4 Results 
 
 
 
 
  
4 Results 
 
43 
 
4.1 DNA nanotubes as intracellular delivery vehicles in vivo 
4.1.1 Design, assembly, and characterization of DNA nanotubes 
 
DNA nanotube design, assembly, and characterization were mainly done by Samet 
Kocabey and Tim Liedl (Department of Physics, LMU Munich) in close cooperation 
and with considerable conceptual input from the author of this thesis. The 
fundamental structure of DNA nanotubes consists of 48 different ODNs, each of 
which is 42 base pairs long. These ODNs self-assemble into a tube-like architecture 
comprised of eight parallel double helices and a designed length of ~40 nm and a 
diameter of ~8 nm (Fig. 6) [34, 117]. The assembly takes place during a temperature-
controlled annealing process. For assembly of CpG nanotubes, 20-nt long CpG 
sequences (CpG 1826) with two highly immunostimulative GACGTT motifs were 
conjugated to DNA nanotubes. 
 
Fig. 6 Schematic illustration of CpG-decorated DNA nanotubes. Left: Mixture of 48 different 
DNA tiles, containing CpG domains (red arrows) or Atto488 dye (green star). Middle: Tiles 
assembled to a secondary tube structure. Blue and green tile domains contain random 
sequences and vertical lines indicate the base pairing. Right: 3D side and front views of 8-
helix DNA nanotubes. Red extensions on the tube surface represent CpG domains and 
transparent cylinders indicate double helices. Taken from Sellner et al. [125]. 
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For the presentation of the CpG 1826 sequences on the surface of the DNA 
nanotubes, 24 of the 48 tile strands were extended on their 3' ends with the CpG 
1826 sequence (Fig. 6).  CpG 1826 belong to B-type CpG sequences and induce an 
immune response via the recognition of the murine TLR 9 located in endosomal 
cellular compartments [32, 126]. 
Unfolded CpG 1826 (CpG ODNs) and DNA nanotubes without CpG motifs (plain 
tubes) served as control samples in all performed experiments. The correct assembly 
of CpG tubes and plain tubes was analyzed by gel electrophoresis and TEM. The 
prominent bands for CpG tubes and plain tubes (Lane 2+3 in Fig. 7A) and the 
decreased mobility of CpG DNA tubes (Lane 2) compared to plain tubes (Lane 3) 
indicate the correct assembly of the structures. TEM micrographs revealed the 
monodisperse composition of the DNA tube architectures, which are with the 
measured length of 41 +/- 1 nm and the measured diameter of 8 +/- 1 nm in 
agreement with the designed dimensions (Fig. 2B and 2C). 
 
 
Fig. 7 Structural characterization of DNA nanotubes. (A) Structural analysis of assembled 
nanotubes by gel electrophoresis after purification. 1) 1 kb ladder, 2) CpG tube 3) plain tube 
and 4) CpG ODNs. Transmission electron micrographs of (B) CpG tubes and (C) plain tubes. 
Scale bars: 100 nm (left) and 40 nm (inset). Taken from Sellner et al. [125]. 
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A prerequisite for the application in vivo is the stability of DNA nanoconstructs in a 
biological environment. Therefore, DNA tubes were treated with different 
concentrations of DNAse I and in different serum conditions for various incubation 
times to analyze the structure stability. Next to CpG ODNs and plain tubes, a double-
stranded plasmid (pUC 18) was used as a control sample. 
For 2 h DNA tubes withstand the degradation caused by DNAse I at a concentration 
which is equivalent to concentrations in murine organs such as pancreas, liver, or 
testis (0.5 U/ml) and is about 40 times higher than the one in skeletal muscle [46]. At 
the same concentration of DNAse I (0.5 U/ml) plasmid pUC18 degraded completely 
within 30 min (Fig. 8A). DNA tubes resisted the treatment with a high dose of DNAse 
I (10 U/ml) up to 15 min whereas plasmid pUC18 was cleaved by DNAse I 
instantaneously (Fig. 8B). Furthermore, DNA nanotubes revealed stable over an 
incubation period of 24 h in serum at a concentration prevalent in the muscle tissue 
(Fig. 8C). CpG DNA nanotubes showed only little degradation under the same 
conditions and time periods (Fig. 8C). However, treatment with pure serum leads to a 
complete degradation of all samples over the course of 2 h (Fig. 8D).     
 
 
 
 
 
 
 
 
  
 
 
Fig. 8 Stability of DNA nanotubes.
to right) incubated in the reaction buffer containing 5 x 10
Gel analysis of CpG tube, plain tube, and pUC 18 (left to 
containing high concentration of DNAse I (10 U/ml) at 37
CpG tube, plain tube and pUC 18 (left to right) incubated in 37x diluted mice serum. (D) Gel 
analysis of CpG tube, plain tube an
inactivated) for 2 h. E) DLS analysis of CpG tube
[125]. 
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4.1.2 Release of inflammatory c
DNA nanotubes and 
 
The purpose of designing CpG DNA tubes was to create
constructs. A simple approach to test the 
nanoconstructs is to measure the cytokine release. Therefore, 
264.7 cells were incubated either with CpG DNA nanotubes
nanotubes (5 nM), CpG ODNs
(5 nM) or LPS (10 ng/ml), w
of TNF into culture supernatants was measured by ELISA
all constructs could be observed in intracellular vesicles 
Fig. 9. Uptake of DNA nanoconstructs and TNF response by RAW 264.7 cells.
cells were incubated with 5 nM of (
ODNs for 3 h at 37 °C. The different DNA nanotubes (red) were internalized by RAW 264.7 
cells. (D, E) ELISA analysis of TNF levels in supernatants of 4x10
incubated for (D) 1 h and (E) 3 h with 5
CpG ODNs, 120 nM of CpG ODNs +
as positive control or without additive (control) (
control). Scale bar: 20 µm. Taken from Sellner et al. 
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Flow cytometric measurements confirmed the uniform cellular uptake of fluorescently 
labeled CpG tubes, plain tubes, plain tubes + CpG ODNs, and CpG ODNs by RAW 
264.7 cells (Fig. 10). Furthermore, the viability of RAW 264.7 cells, up to 18 hours of 
incubation with DNA nanoconstructs, was not affected (Fig. 11). Although there are 
no differences in cellular uptake and viability, the cellular production of TNF varied 
between the different groups. Incubation with CpG DNA tubes led within 1 h to a 3-
fold and within 3 h to a 5-fold higher induction of TNF release compared to untreated 
cells (Fig. 9D, E). Treatment with plain tubes, CpG ODNs, and CpG ODNs + plain 
tubes induced only a slight increase of TNF after 3 h (Fig. 9E).  
These results allow the conclusion that CpG DNA nanotube structures are 
immunogenic within 3 h of treatment. The complexation of CpG ODNs on the DNA 
tubes seems to be essential for the recognition of CpG sequences and the 
subsequent cellular TNF production.   
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Fig. 10 Uptake of DNA nanoconstructs by RAW 264.7 macrophages after 1 h of incubation. 
Representative histograms show a fluorescence shift indicating the uptake of Cy3-coupled 
DNA nanoconstructs by RAW 264.7 macrophages. Cells were incubated with different DNA 
nanoconstructs (5 nM CpG DNA tubes, 5 nM DNA tubes, 120 nM CpG ODNs, 120 nM CpG 
ODNs + 5 nM DNA tubes), LPS (10 ng/ml) or without additive (control) for 1 h at 37°C. Taken 
from Sellner et al. [125].  
 
 
 
 
 
 
 
 
Control 
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Fig.11 Cell viability after incubation with DNA nanoconstructs. FACS analysis of RAW 264.7 
macrophage viability after incubation with different DNA nanoconstructs (5 nM CpG DNA 
tubes, 5 nM DNA tubes, 120 nM CpG ODNs, 120 nM CpG ODNs + 5 nM DNA tubes), LPS 
(10 ng/ml) or without additive for 1 h (A) and 18 h (B) at 37 °C. The numbers indicate the 
percentage of viable cells within the sample. Taken from Sellner et al. [125]. 
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4.1.3 Localization of DNA nanotubes in skeletal muscle tissue 
after microinjection
 
Next, the behavior of DNA nanotubes in the skeletal musc
For this purpose, fluorescently 
the murine cremaster muscle
fluorescence microscopy was performed to 
Perivascular and tissue-resident cells in the vicini
CpG DNA nanotubes within 5 
pattern was the same for all DNA nanoconstructs
Fig. 12 Distribution of CpG DNA nanotubes in the cremaster tissue.
microscopy images of CpG tube (red) distribution after microinjection into the cremaster 
muscle revealed a rapid uptake of CpG tubes by tissue
vicinity of the application site (arrow). At 30 min and 60 min, 
visible in the tissue adjacent to the postcapillary venule (
fluorescence channel images (
from the cremaster tissue (
microinjection of 250 nl of CpG 
from Sellner et al. [125]. 
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le tissue 
labeled DNA nanoconstructs were microinjected i
 in 25 µm to 50 µm distance to a venule
visualize the DNA constructs for 60 min.
ty of the injection site
min after microinjection (Fig. 12A and
 (Data not shown). 
 In vivo
-resident cells (arrowheads) in the 
transmigrated leukocytes are 
A, B) to the injection site. The 
B) are merged with the corresponding transmitted light images 
A). Images were taken at the indicated time points after 
tubes and selected from a movie. Scale bar: 50 µm
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The identification of these perivascular 
repeated microinjection of DNA nanoconstructs into the cremaster muscle of 
EGFP transgenic (MacGreen)
extend polymorphonuclear leukocytes express green fluorescent protein under the 
control of the CSF-1R (c-fms) promoter. 
Fig. 13 DNA nanotubes are localized in the endolysosomes of tissue macrophages.
imaging of CpG tubes (A-C) and plain tubes (
MacGreen mice. Images show that DNA nanotubes (
positive macrophages (B, E, green). The fluorescence channel images (
merged with the corresponding transmitted light images depicting the muscle tissue (
Scale bar: 30 µm. Confocal imaging of co
LysoTracker (green) showing the presence of CpG tubes (
late endolysosomes (H, K). Merged image (
[125]. 
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After microinjection of CpG tubes, plain tubes, and CpG ODNs, the constructs could 
be localized in vesicular structures of EGFP+ tissue-resident macrophages (Fig. 13A-
F). Simultaneous microinjection of DNA nanostructures and LysoTracker dye 
demonstrated that DNA nanostructures are localized in the endolysosomes of tissue-
resident macrophages (Fig. 13G-L). 
Consistent with the in vitro results, the cellular uptake pattern of CpG tubes, plain 
tubes, and CpG ODNs in vivo are identical. However, plain tubes and CpG tubes 
accumulate along muscle fibers, which have been pierced by glass capillaries during 
microinjection (Fig. not shown). Furthermore, CpG as well as DNA tubes were 
attached to extracellular matrix components, presumably collagen fibers (Fig 12 and 
Fig. 13). 
 
4.1.4 Microinjection of CpG tubes induces leukocyte adhesion 
and transmigration 
 
In additional experiments, the impact of DNA nanotubes on leukocyte recruitment 
was investigated. Using near-infrared transillumination in vivo microscopy, firm 
adherence and transmigration of leukocytes were analyzed in the mouse cremaster 
muscle up to 90 min after microinjection of DNA nanoconstructs.  
30 min after application of CpG tubes the numbers of firmly adherent leukocytes (3.5 
+/- 0.31/104 µm2) at the vessel walls of postcapillary venules were significantly 
increased compared to the injection of plain tubes (0.75 +/- 0.35/104 µm2) or CpG 
ODNs (0.64 +/- 0.48/104 µm2)(Fig. 14A). As shown in Figure 14B, these significant 
higher numbers of adherent leukocytes after CpG nanotube administration 
maintained over 60 min of observation since the numbers of adherent leukocytes 
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after CpG nanotube microinjection (2.89 +/- 0.23/104 µm2) was five times higher than 
in the control group receiving saline (0.67 +/- 0.31/104 µm2). The numbers of 
adherent leukocytes after CpG ODN microinjection remained low (0.87 +/- 0.26/104 
µm2), whereas administration of plain tubes elevated the numbers of adherent cells 
after 60 min (2.31 +/- 0.56/104 µm2) 4-fold compared to the saline group. In 
accordance with the typical length of time for the different steps of leukocyte 
recruitment upon administration of inflammatory mediators [128] the number of 
adherent leukocytes declined 90 min after injection of CpG DNA nanotubes (Data not 
shown).  
After adhesion, leukocytes subsequently transmigrate from the vessel lumen into the 
inflamed tissue. To test whether local microinjection of the different constructs 
resulted in a directed transmigration of leukocytes into the adjacent tissue, a 
comparison of the numbers of transmigrated cells on the vessel side ipsilateral to the 
application site with those on the contralateral side was conducted. In line with the 
leukocyte adherence data, the numbers of transmigrated leukocytes were 
significantly increased within the ipsilateral vessel side after CpG DNA microinjection 
(Fig. 14D, 60 min: 7.3 +/- 0.32/104 µm2) as compared to saline (Fig. 14D, 60 min: 1.3 
+/- 0.51/104 µm2) at all investigated time points (Fig. 14C and D). However, 
microinjection of CpG ODNs or plain DNA tubes had no effect on leukocyte 
transmigration. 
Taken together, these data demonstrate the immunogenic properties of CpG-
decorated DNA tubes. CpG DNA nanotubes recruit leukocytes to the site of injection, 
whereas plain DNA tubes and CpG ODNs lack this capacity. 
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Fig. 14 Quantitative analysis of intravascular adherence and transmigration of leukocytes 
after microinjection of DNA nanoconstructs. Leukocyte adherence was quantified in 
postcapillary venules in the cremaster muscle using in vivo transillumination microscopy at 
30 min (A) and 60 min (B) upon microinjection of CpG tubes, DNA tubes, CpG ODNs, or 
saline. The numbers of adherent leukocytes were significantly increased at 30 min and 60 
min after CpG tube injection. Pretreatment with cromolyn prior to CpG tube injection 
diminished leukocyte adherence. Leukocyte transmigration was quantified on the vessel side 
ipsilateral to the microinjection site (white bars) and on the contralateral side (black bars) at 
30 min (C) and 60 min (D) after microinjection. CpG tube injection elicited leukocyte 
transmigration into the tissue. Cromolyn pretreatment attenuated the leukocyte 
transmigration induced by microinjection of CpG tubes (n=6, mean+/-SEM; *p<0.05, 
**p<0.01, ***p<0.001 vs. all groups). (E, F) depicts representative in vivo microscopy images 
of postcapillary venules in the cremaster muscle 30 min after microinjection of either saline 
(E) or CpG tubes (F) with adherent as well as transmigrated leukocytes. Scale bar, 25 µm. 
Taken from Sellner et al. [125]. 
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4.1.5 Mast cell inhibition abolishes CpG tube-evoked leukocyte   
adhesion and transmigration 
 
Mast cells are well known for their role in allergy, since they are important immune 
cells involved in the recognition of pathogens and the initiation of immune responses 
[129]. After activation, mast cells are able to release proinflammatory mediators from 
their characteristic granules, which subsequently facilitate the exit of leukocytes from 
postcapillary venules [130]. As previously reported, surgical preparation of the 
cremaster muscle does not activate mast cells and does not contribute to the low 
baseline levels of preparation-induced leukocyte recruitment [124, 131].
 
To determine 
whether mast cells are involved in leukocyte recruitment elicited by microinjection of 
CpG DNA nanotubes, mice received the mast cell degranulation inhibitor cromolyn 
prior to microinjection.     
Cromolyn pretreatment diminished the numbers of adherent (Fig. 14B, 60 min, 1.3 +/- 
0.33/104 µm2) and the numbers of transmigrated leukocytes (Fig. 14D, 60 min, 1.7 +/- 
0.71/104 µm2) after microinjection of CpG tubes compared to non-treated mice (Fig. 
14B, adherence 60 min, 2.8 +/- 0.24/104 µm2, Fig. 14D, transmigration 60 min, 7.3 +/- 
0.48/104 µm2). These values were in the range of the control group (Fig. 14B, 
adherence 60 min, 0.7 +/- 0.32/104 µm2, Fig. 14D, transmigration 60 min, 1.3 +/- 
0.62/104 µm2). 
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4.1.6 Systemic leukocyte counts and microhemodynamic 
parameters 
 
To guarantee the comparability of all experimental groups, inner vessel diameter, 
blood flow, and wall shear stress of all examined vessels were determined. To 
exclude anomalies, systemic leukocyte counts in the peripheral blood of animals 
were measured at the end of the experiment. There were no significant differences in 
inner vessel diameter, blood flow, wall shear stress, or systemic leukocyte counts 
between all groups (Table 1). 
 
 Experimental 
group 
Inner 
vessel 
diameter 
[µm] 
Blood flow 
velocity 
  
[mm/s] 
Wall shear rate 
 
 
[1/s] 
Systemic 
leukocyte 
counts 
[ *106 /ml] 
 
      
 
 
Sham 29.2 ± 2.0 3.1 ± 1.2 4157.6 ± 1650.2 3.6 ± 1.4 
 Saline 
 
27.8 ± 1.2 2.8 ± 0.7 3978.1 ± 1075.8 2.4 ± 0.7 
 CpG 
nanotubes 
 
31.8 ± 3.1 3.1 ± 1.1 3800.0 ± 1175.2 2.7 ± 1.5 
 
 
DNA 
nanotubes 
25.8 ± 0.8 3.5 ± 0.3 5312.6 ± 291.2 1.8 ± 0.1 
      
 CpG ODNs 
 
27.3 ± 1.5 2.6 ± 0.6 3726.7 ± 907.1 4.5 ± 1.0 
 
Table 1 Systemic leukocyte counts and microhemodynamic parameters. Systemic leukocyte 
counts as well as microhemodynamic parameters, including inner vessel diameter, blood 
flow velocity, and wall shear rate, were obtained as detailed in Materials and Methods (mean 
± SEM for n=4-5 per group). Taken from Sellner et al. [125]. 
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4.1.7 CpG tube microinjection results in NF-ĸB pathway 
activation 
 
The transcription factor NF-ĸB is a key regulator of genes involved in inflammatory 
processes. Binding of TLR ligands leads to a downstream activation of NF-ĸB and 
the subsequent translocation from the cytoplasm into the nucleus [132, 133], where 
the expression of inflammatory mediators such as TNF and IL-1 is mediated [134]. 
Immunostaining of phosphorylated p65, a subunit of the NF-ĸB complex, which 
indicates nuclear NF-ĸB [135], was performed with DNA nanoconstructs-
microinjected cremasteric tissue to investigate the ability of CpG nanotubes to induce 
NF-ĸB activation. 
A clear nuclear localization of phospho-p65 could be detected in cells close to the 
CpG nanotube injection site 90 min upon microinjection (Fig. 15B and E), which was 
not present in plain tube- (Fig. 15A and D) and CpG ODN- (Fig. 15C and F) injected 
tissues. The majority of the phospho-p65-positive cells accumulated around the site 
of CpG DNA tube administration exhibited roundish nuclei, similar to multi-lobed 
granulocyte nuclei (Fig. 15B and E), whereas p65-positive cells with elongated nuclei 
are presumably tissue-resident cells, such as macrophages or mast cells.  
  
Fig. 15 NF-ĸB p65 translocation occurs in the vicinity of microinjected CpG DNA nanotubes.
Confocal immunofluorescence of DNA nanotubes (red), NF
(blue) counterstaining showed marked NF
injection site of CpG tubes (B, 
the cremasteric tissue (C, F) caused only weak nuclear p65 staining. Scale 
Taken from Sellner et al. [125
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To determine the local distribution of CpG DNA nanoconstructs within 
muscle tissue, real-time fluorescence intravital microscopy
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the local microdistribution of DNA nanotubes needs to be investigated to test the 
therapeutic potential of the constructs in the postischemic tissue.  
 
Fig. 16 Uptake of DNA nanoconstructs by tissue macrophages in inflamed cremasteric 
tissue. Confocal imaging of CpG tubes, plain tubes, and CpG ODNs microinjected in the 
postischemic cremaster muscle. Images show that DNA nanoconstructs (red) were 
internalized by tissue-resident macrophages in the inflamed cremaster tissue. The 
fluorescence channel images are merged with the corresponding transmitted light images 
depicting the muscle tissue. Scale bar: 50 µm.  
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By means of in vivo fluorescence microscopy, 30 min after microinjection of CpG 
DNA nanotubes (500 nM), plain nanotubes (500 nM), and CpG ODNs (12 µM), the 
constructs were found within cells, associated with postcapillary venules as depicted 
in Figure 16. The cell morphology as well as our previous experiments suggests that 
the DNA nanoconstructs were incorporated by tissue macrophages. Additionally, 
DNA tubes were prominently localized along distinct tissue structures, presumably 
collagen fibers (Fig. 16). However, DNA nanoconstructs could not be detected in ECs 
or transmigrated leukocytes. During the observation period of 90 min, the 
nanoconstructs remained inside macrophages and along tissue fibers (Data not 
shown). 
  
4.2.2 Microinjection of CpG tubes into ischemic muscle tissue 
attenuates leukocyte adhesion and transmigration 
 
Real-time fluorescence intravital microscopy was used to investigate the effects of 
CpG DNA nanoconstructs on leukocyte infiltration into the postischemic mouse 
cremaster muscle.  
At baseline conditions and after release of the vascular clamp, the number of 
leukocytes attached to the inner vessel wall of postcapillary venules was low and did 
not differ among experimental groups (Data not shown). After 60 min of reperfusion, 
microinjection of CpG DNA nanotube or saline lead to similar numbers of firmly 
adherent leukocytes (Fig. 17A, CpG DNA: 3.3 +/- 0.99/104 µm2; saline: 3.5 +/- 
0.99/104 µm2) while DNA nanotube microinjection caused highly elevated numbers of 
leukocytes (Fig. 17A, 10 +/- 4.59/104 µm2). Within 90 min this elevated numbers after 
DNA nanotube administration diminished. However, the numbers of adherent 
4 Results 
 
62 
 
leukocytes after CpG nanotube microinjection (Fig. 17B, 1.4 +/- 0.72/104 µm2) 
dropped under these of saline injection (Fig. 17B, 3.8 +/- 0.9/104 µm2). Microinjection 
of CpG ODNs into the postischemic muscle tissue resulted in a similar number of 
adherent cells compared to microinjection of saline over the observation period of 90 
min (Fig. 17B, 60 min: 2.9 +/- 0.7/104 µm2; 90 min: 2.9 +/- 0.7/104 µm2). Before onset 
of ischemia, only few transmigrated leukocytes were found within the perivenular 
tissue (Data not shown). Consistent with the results obtained for leukocyte firm 
adherence, the numbers of transmigrated leukocytes detected within the perivascular 
tissue were elevated after DNA nanotube application at all investigated time points 
(Fig. 17C, 60 min: 15 +/- 4.5/104 µm2; Fig. 17D, 90 min: 22 +/- 5.8/104 µm2) as 
compared to sham-treated mice. The numbers of transmigrated leukocytes after 
microinjection of CpG tubes were less than after saline at 60 min (Fig. 17C, CpG 
DNA nanotubes: 8.5 +/- 1.9/104 µm2; saline: 12.8 +/- 2.8/104 µm2) but rose after 90 
min to the saline (I/R control) level (Fig. 17D, CpG DNA nanotubes: 13 +/- 2.1/104 
µm2; saline: 12.2 +/- 2.2/104 µm2). Microinjection of CpG ODNs had an inhibitory 
effect on the transmigration of leukocytes at 60 min (Fig. 17C, 5 +/- 1.5/104 µm2) and 
90 min (Fig. 17D, 7.4 +/- 2.1/104 µm2) of reperfusion.   
Taken together, these data indicate that CpG ODNs attenuate the recruitment of 
leukocytes into ischemic tissue, whereas plain DNA tubes enhance the leukocyte 
response under sterile inflammatory conditions.  
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Fig. 17 Quantitative analysis of intravascular adherence and transmigration of leukocytes 
after microinjection of DNA nanoconstructs into postischemic tissue at the onset of 
reperfusion. Leukocyte adherence was quantified in postcapillary venules in the cremaster 
muscle using in vivo transillumination microscopy at 60 min (A) and 90 min (B) upon 
microinjection of CpG tubes, DNA tubes, CpG ODNs, saline, or in sham-operated animals. 
The numbers of adherent leukocytes were increased at 60 min and 90 min after DNA 
nanotube injection, whereas CpG constructs attenuated the numbers. Leukocyte 
transmigration was quantified at 60 min (C) and 90 min (D) after microinjection. CpG ODN 
injection attenuated leukocyte transmigration into the tissue, whereas DNA tube application 
elevated the numbers of transmigrated leukocytes (n=6, mean+/-SEM, *p<0.05, **p<0.01 vs. 
all groups). 
 
4.2.3 Systemic leukocyte counts and microhemodynamic 
parameters 
 
To assure intergroup comparability, systemic leukocyte counts, inner vessel 
diameter, blood flow, and wall shear stress were measured at the end of the 
experiments. No significant differences in these parameters were detected among all 
experimental groups (Table 2). 
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 Experimental 
group 
Inner 
vessel 
diameter 
[µm] 
Blood flow 
velocity 
  
[mm/s] 
Wall shear rate 
 
 
[1/s] 
Systemic 
leukocyte 
counts 
[*106 /ml] 
 
 
     
 Saline 28.0 ± 0.5 2.8 ± 0.3 3978.0 ± 537.9 2.6 ± 0.3 
 
 Sham 27.8 ± 1.6 3.1 ± 0.6 4158.0 ± 825.1 3.8 ± 0.5 
 
 DNA 
nanotubes 
27.3 ± 1.2 3.5 ± 0.2 5313.0 ± 168.1 2.1 ± 0.3 
 CpG 
nanotubes 
30.1 ± 1.3 3.1 ± 0.6 3800.0 ± 587.6 3.2 ± 0.9 
 
 
CpG ODNs 
 
26.5 ± 0.7 2.6 ± 0.3 3726.0 ± 523.7 2.0 ± 0.2 
Table 2 Systemic leukocyte counts and microhemodynamic parameters. Systemic leukocyte 
counts as well as microhemodynamic parameters, including inner vessel diameter, blood 
flow velocity, and wall shear rate, were obtained as described in Materials and Methods 
(mean ± SEM for n=4 per group). 
 
4.2.4 Microinjection of CpG tubes into postischemic muscle   
tissue increases cellular TLR 9 expression 
 
To determine the TLR 9 expression upon DNA nanoconstruct microinjection, confocal 
microscopy of TLR 9 immunostained-postischemic muscle tissue was performed. 
Notably, 90 min upon microinjection of CpG DNA tubes, a multitude of cells with 
elongated, ramified shapes and intense TLR 9 signal were present around the 
injection site (Fig. 18A and E). Surprisingly, the cellular TLR 9 signal was not 
localized in vesicular structures but ubiquitously present over the whole cell bodies. 
Microinjection of CpG DNA tubes into the postischemic cremaster of a CX3CR1GFP 
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mouse revealed that these TLR 9high cells are CX3CR1GFP-positive macrophages (Fig. 
19A-D). I/R injury together with CpG DNA tube microinjection induced a substantial 
change in the morphology of these macrophages (Fig. 19B), since CX3CR1GFP-
positive macrophages did not display prominent TLR 9 expression after saline 
injection (Fig. 19E-H). The administration of CpG ODNs in the ischemic cremaster 
tissue had only little impact on macrophage morphology. The cellular TLR 9 signal 
was markedly less pronounced and macrophages with long protrusions were not 
present (Fig. 18C and G). Also microinjection of plain tubes induced just weak TLR 9 
expression (Fig 18B and F).  
In all three groups, TLR 9 was present at blood vessel walls. Vascular TLR 9 staining 
was either spotted (Fig. 18B and F), or was present section-wise (Fig. 18C and G) 
after microinjection of plain tubes and CpG ODNs. 
Fig. 18 Marked TLR 9 expression in ramified macrophages upon microinjection of CpG tubes 
into the postischemic cremaster muscle. Confocal immunofluorescence of CpG DNA 
nanoconstructs (red), TLR 9 (green), and TO-PRO (blue) counterstaining showed marked 
cellular TLR 9 staining after the injection of CpG tubes (A, E) into postischemic tissue. 
Injection of plain tubes (B, F), CpG ODNs (C, G), and saline (D, H) into postischemic 
cremasteric tissue caused only weak TLR 9 expression in interstitial cells. Scale bar: 50 µm. 
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Fig. 19 TLR 9 expression in CX3CR1GFP macrophages after injection of CpG nanoconstructs 
and saline into the postischemic cremaster muscle. Confocal immunofluorescence images of 
CpG nanotubes (A-D) and saline (E-H) microinjected into the cremaster muscle of 
CX3CR1GFP mice, which were immunostained for TLR 9 (red) and cell nuclei (TO-PRO, blue).  
Injection of CpG nanotubes induced TLR 9 (red) expression (C) in CX3CR1GFP-positive 
macrophages (green) compared to saline (G). Scale bar: 50 µm. 
 
4.3 Dexamethasone-conjugated DNA nanotubes as anti-
inflammatory agents in vivo 
4.3.1 Characterization and functionality of Dex nanotubes  
 
Dex nanotube design, assembly, and characterization were mainly done by Samet 
Kocabey and Tim Liedl (Department of Physics, LMU) in close cooperation and with 
considerable conceptual input by the author of this thesis.  
A DNA nanotube construct, consisting of 15 unique single-stranded tiles, with a ph-
responsive i-motif was designed as controllable device for the intracellular release of 
the anti-inflammatory drug dexamethasone (Fig. 20A). In order to conjugate 
dexamethasone on the structure, 3 of the tiles were extended from their 3´ ends with 
an i-motif sequence or a random sequence, which then hybridize with Dex ODNs. 
The temperature-controlled assembly of the tiles into 6 parallel double helices led to 
  
a tube structure with a designed length of ~30 nm and a diameter of ~8 nm. TEM 
micrographs revealed the c
DNA tubes, Dex nanotubes
dexamethasone (Dex ODNs)
structure is a four-stranded DNA structure
of cytosine residues [139-141
Fig. 20 Characterization of Dex DNA nanoconstructs
nanotubes with i-motif-dependent dexamethasone release
micrograph of a single DNA nanotube. Scale bar 
dependent release of the hybridized 
from Dex nanotubes labeled with SYBR green
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Cytosines in the i-motif sequence get protonated at low pH and form a quadruple 
helix. This mechanism was used to release Dex ODNs upon acidic pH as illustrated 
in Figure 20A. To test the functionality of the i-motif-dependent release mechanism, 
the nanotubes were incubated in MES buffer (pH 5.5) at 37 °C and centrifuged to get 
rid of released single-stranded tiles. Gel analysis revealed that Alexa 647-labeled 
complementary tiles are still visible at structures without i-motif sequence and on 
structures incubated in buffer at pH 8. However, the i-motif-dependent release of 
hybridized ODNs at pH 5.5 could be observed since the Alexa 647 signal is very low 
in comparison to the control groups (Fig. 20C). The released Dex ODNs were 
washed out during the centrifugation process. This experiment demonstrated the i-
motif-dependent release of Dex ODNs from DNA 6-helix tubes at 37 °C and under 
acidic pH.   
 
4.3.2 Dexamethasone-conjugated DNA nanoconstructs do not 
affect macrophage viability 
 
The synthetic glucocorticoid dexamethasone is reported to have cytotoxic effects on 
several cell types [142-144]. Although the dexamethasone concentrations applied in 
vitro with DEX tubes are low (40 ng/ml), the cell vitality during treatment with the 
different nanoconstructs were tested. For in vitro testing, a murine alveolar 
macrophage cell line (MH-S) was used in this study, since dexamethasone is a 
potent agent targeting the cytokine release from alveolar macrophages in asthma 
therapy [145, 146].   
Cytotoxic effects of Dex tubes, DNA tubes, Dex ODNs, Dex tubes w/o i-motif (all at 
50 nM), unconjugated dexamethasone (40 ng/ml and 1 µg/ml), and LPS (10 ng/ml) 
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on MH-S macrophages were examined using the WST-1 assay. Dexamethasone 
was used in a concentration equivalent to the concentration on Dex tubes (40 ng/ml) 
and in a higher dose, described to be immunosuppressive (1 µg/ml) [147]. DNA 
nanoconstructs, as well as free dexamethasone were not cytotoxic for MH-S cells 
over a time period of 12h (Fig. 21). MH-S cells were also exposed for 2 min to 70% 
ethanol (EtOH) and afterwards medium was added. This treatment led to cell death 
and served as negative control. After 6 h of incubation, the cell viability increased 
almost to 150% of the untreated control cells (100%), which corresponds with higher 
metabolic rates of NADH (mediating the complex formation of the tetrazolium salt 
WST-1) before macromolecular synthesis and cell division [148]. 
 
Fig. 21 Effects of Dex nanoconstructs on MH-S macrophage cell viability. MH-S 
macrophages were incubated with medium containing Dex tubes (50 nM), DNA tubes (50 
nM), Dex ODNs (50 nM), Dex DNA tubes w/o i-motif (50 nM), dexamethasone (40 ng/ml and 
1 µg/ml), and LPS (10 ng/ml) for 12 h. 70% ethanol was added for 2 min and served as 
negative control. Cell viability was evaluated using the colorimetric WST1-assay. 
 
4.3.3 Dex tubes are effectively incorporated by macrophages 
  
Dex tubes could be rapidly detected within MH-S macrophages. Already within 15 
min of incubation with Dex nanoconstructs, Dex tubes could be detected within 
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intracellular vesicles (Fig. 22A), but to a lesser extent than Dex tubes w/o i-motif (Fig. 
22D). Apparently, the overall uptake rate differed between the various Dex 
nanoconstructs, although the administered concentrations were equal. Plain DNA 
tubes were preferably incorporated by MH-S cells (Fig. 22B), whereas Dex ODNs 
could hardly be detected in phagosomal structures (Fig. 22C).  
Within 6 h of incubation Dex DNA tubes and plain DNA tubes were equally present in 
cellular compartments of MH-S cells (Fig. 23A and B). Interestingly, at 6 h the 
colocalization of Alexa 546 Dex ODNs with the Alexa 488-conjugated DNA tube 
structure could no longer be observed, whereas Dex ODNs were still present in the 
endolysosomal compartments (Fig. 23C). Since the functionality of the i-motif could 
be shown at pH 5.5 and 37 °C (Fig. 20C), this loss of endolysosomal Alexa 546 
fluorescence might indicate the escape of dexamethasone from this compartment. 
On the contrary, Dex tubes w/o i-motif still showed a colocalization of Alexa 546 Dex 
handles and the Alexa 488-linked DNA tube structure, after 6 h. Noticeable, the 
construct distribution changed from purely vesicular to vesicular/cytoplasmatic in the 
majority of MH-S cells with incorporated constructs (Fig. 23D). This phenotype was 
correlated with the accumulation of cells and the formation of giant cells (Data not 
shown), suggesting an activated status. Furthermore, within 6 h of incubation, 
vesicles containing Dex nanoconstructs clustered around the cellular nuclei (Fig. 
23A-D). This indicates a maturation of these vesicles from early to late endosomes, 
which are in close proximity to the Golgi apparatus and the nucleus.    
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Fig. 22 Uptake of DNA nanoconstructs by MH-S macrophages within 15 min of incubation. 
MH-S cells were incubated with 50 nM Dex tubes (A), 50 nM plain tubes (B), 150 nM Dex 
ODNs (C), 50 nM Dex tubes w/o i-motif (D), or without additive (control) (E) for 15 min at 37 
°C. Confocal fluorescence microscopy of Alexa 488-labeled DNA nanotubes (green), 
separately Alexa 546-labeled Dex handles (red) and TO-PRO (cell nuclei, blue) 
counterstaining showed a vesicular localization of DNA nanoconstructs within 15 min of 
incubation. Scale bar: 20 µm. 
 
 
 
4 Results 
 
72 
 
 
Fig. 23 Uptake of DNA nanoconstructs by MH-S macrophages within 6 h of incubation. MH-
S cells were incubated with 50 nM Dex tubes (A), 50 nM plain tubes (B), 150 nM Dex ODNs 
(C), 50 nM Dex tubes w/o i-motif (D), or without additive (control) (E) for 6 h at 37 °C. 
Confocal fluorescence microscopy of Alexa 488-labeled DNA nanotubes (green), separately 
Alexa 546-labeled Dex handles (red) and TO-PRO (cell nuclei, blue) counterstaining 
revealed a vesicular localization of DNA nanoconstructs after 6 h of incubation. Scale bar: 20 
µm. 
Taken together, it can be concluded that the uptake of Dex nanoconstructs by MH-S 
cells occurs within the first minutes of incubation. DNA tubes, Dex tubes, Dex tubes 
w/o i-motif, and Dex ODNs are stored up to 6 h in endolysosomal compartments of 
MH-S macrophages, but only Dex tubes with functional i-motif lost the Dex handle 
signal after 6 h.    
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4.3.4 Dex tubes attenuate LPS-induced TNF secretion by MH-S 
macrophages 
 
Next, the pH-responsive Dex nanoconstructs were tested on their ability to suppress 
pro-inflammatory cytokine release in response to LPS. Accordingly, MH-S alveolar 
macrophages were incubated for 15 min with the respective Dex nanoconstruct, 
which was removed prior to LPS stimulation.  
Dex tubes showed a significant inhibitory effect on TNF release (12 h: 306 +/- 9.6 
pg/ml) up to 12 h of LPS stimulation compared to LPS without DNA construct 
pretreatment (12 h: 547 +/- 35.4 pg/ml) (Fig. 24). Pretreatment with 40 ng/ml 
dexamethasone, a concentration equivalent to Dex tubes reduced the TNF release of 
MH-S cells only for 6 h (6 h: 164.1 +/- 7.3 pg/ml; 12 h: 476 +/- 13.1 pg/ml) (Fig. 24). 
In contrast, pretreatment with Dex tubes w/o i-motif intensified the LPS induced TNF 
response of MH-S cells from 6 h to 12 h of LPS stimulation (6 h: 851 +/- 40.1 pg/ml; 
12 h: 1304.4 +/- 28.6 pg/ml). Plain DNA tubes did not affect the release of TNF by 
MH-S cells (12 h: 508.1 +/- 15.8 pg/ml) since the secreted levels were comparable to 
the LPS control group over 12 h. Incubation with Dex ODNs did not result in a 
significant inhibition of TNF release upon LPS stimulation. 
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Fig. 24 TNF release by MH-S cells induced by LPS stimulation is attenuated after 
pretreatment with Dex tubes. ELISA analysis of TNF levels in supernatants of 1x105 MH-S 
cells incubated for 1 h, 3 h, 6 h, and 12 h with LPS (10 ng/ml) and pretreated for 15 min with 
50 nM Dex tubes, 50 nM Dex tubes w/o i-motif, 50 nM DNA tubes, 150 nM Dex ODNs, and 
dexamethasone (1 µg/ml and 40 ng/ml) or without additive (control). (n=3, mean+/-SEM; 
*p<0.05, **p<0.01, ***p<0.001 vs. control)  
 
 
 
4.3.5 Microinjection of Dex tubes into postischemic muscle 
tissue lowers the number of adherent and transmigrated 
leukocytes 
 
It has been shown that dexamethasone mediates its immunosuppressive effect by 
affecting the recruitment of leukocytes [149].  
In vivo transillumination microscopy was performed to analyze the impact of Dex 
nanotubes on leukocyte infiltration. Therefore, Dex nanoconstructs as well as 
unconjugated dexamethasone (1 µg/ml) were microinjected into the mouse 
cremaster muscle at the onset of reperfusion after an ischemic period of 30 min. At 
baseline conditions and after release of the vascular clamp, the number of leukocytes 
attached to the inner vessel wall of postcapillary venules was low and did not differ 
among experimental groups (Data not shown). Within 60 and 90 min of reperfusion, 
the numbers of firmly adherent leukocytes after microinjection of Dex tubes (60 min: 
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4.3 +/- 1.4 /104 µm2; 90 min: 2.6 +/- 1.1 /104 µm2) kept at the level of saline-injected 
animals (60 min: 3.5 +/- 1.0 /104 µm2; 90 min: 3.8 +/- 0.9 /104 µm2), whereas 
significantly elevated numbers of adherent leukocytes could be observed after Dex 
ODN injection (60 min: 18.8 +/- 7.3 /104 µm2; 90 min: 17.6 +/- 6.7 /104 µm2) (Fig. 25A 
and B). Injection of unconjugated dexamethasone led to higher numbers of adherent 
leukocytes at both time points compared to Dex tubes (1 µg/ml; 60 min: 7.3 +/- 2.8 
/104 µm2; 90 min: 7.0 +/- 2.6 /104 µm2). The same applies for microinjection of Dex 
tubes w/o i-motif (60 min: 12.6 +/- 2.6 /104 µm2; 90 min: 8.8 +/- 2.4 /104 µm2) and 
plain DNA tubes (60 min: 9.7 +/- 3.0 /104 µm2; 90 min: 9.9 +/- 2.7 /104 µm2) (Fig. 25A 
and B). 
Before ischemia, only few transmigrated leukocytes were found within the perivenular 
tissue (Data not shown). The numbers of transmigrated leukocytes detected within 
the perivascular tissue after Dex DNA nanotube application (60 min: 2.8 +/- 0.9 /104 
µm2; 90 min: 4.2 +/- 1.6 /104 µm2) were as low as in sham-operated animals (60 min: 
2.2 +/- 0.7 /104 µm2; 90 min: 4.2 +/- 1.6 /104 µm2) at all investigated time points (Fig. 
25C and D). The numbers of transmigrated leukocytes after microinjection of DNA 
nanotubes (60 min: 13.0 +/- 7.1 /104 µm2; 90 min: 16.3 +/- 6.5 /104 µm2), Dex ODNs 
(60 min: 10.7 +/- 2.8 /104 µm2; 90 min: 16.8 +/- 3.7 /104 µm2), and unconjugated 
dexamethasone (1 µg/ml; 60 min: 12.5 +/- 6.0 /104 µm2; 90 min: 12.0 +/- 6.1 /104 
µm2) were comparable to the saline-injected control animals (60 min: 12.8 +/- 2.8 
/104 µm2; 90 min: 12.2 +/- 2.2 /104 µm2). Interestingly, Dex tubes w/o i-motif had a 
contrary effect on leukocyte extravasation than their i-motif carrying counterparts (60 
min: 21.3 +/- 4.8 /104 µm2; 90 min: 24.2 +/- 5.5 /104 µm2). The number of 
transmigrated leukocytes into the postischemic tissue was higher than in any other 
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Taken together, these data indicate that Dex tubes attenuate the recruitment of 
leukocytes into postischemic tissue, whereas Dex tubes w/o i-motif increase 
leukocyte recruitment under these sterile inflammatory conditions. 
 
 
Fig. 25 Quantitative analysis of intravascular adherence and transmigration of leukocytes 
after microinjection of Dex nanoconstructs. Leukocyte adherence was quantified in 
postcapillary venules of the cremaster muscle using in vivo transillumination microscopy at 
60 min (A) and 90 min (B) upon microinjection of Dex tubes, DNA tubes, Dex ODNs, Dex 
tubes w/o i-motif, dexamethasone, or saline into postischemic cremaster tissue at onset of 
reperfusion. The numbers of adherent leukocytes after injection of Dex tubes were as low as 
after injection of saline at 60 min and 90 min after reperfusion. Leukocyte transmigration was 
quantified at 60 min (C) and 90 min (D) after microinjection. Dex tube injection attenuated the 
transmigration of leukocytes into the tissue, whereas Dex tubes w/o i-motif induced 
transmigration of leukocytes into the postischemic tissue. (n=6, mean+/-SEM; *p<0.05 vs. all 
groups) 
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4.3.6 Systemic leukocyte counts and microhemodynamic 
parameters 
 
Inner vessel diameter, wall shear stress, and blood flow velocities of analyzed 
postcapillary venules as well as leukocyte counts were determined to ensure 
intergroup comparability. No significant differences were present in the experimental 
groups (Table 3). 
 Experimental 
group 
Inner 
vessel 
diameter 
[µm] 
Blood flow 
velocity 
  
[mm/s] 
Wall shear rate 
 
 
[1/s] 
Systemic 
leukocyte 
counts 
[*106/ml] 
 
      
 
 
 
Sham 27.8 ± 1.6 3.7 ± 0.3 4907 ± 446.8 3.8 ± 0.5 
 Saline 28.0 ± 0.5 3.1 ± 0.3 4349 ± 508.2 2.7 ± 0.3 
 
Dex tubes 
 
Dex tubes w/o 
i-motif 
 
28.9 ± 2.0 
 
30.5 ± 2.2                     
3.7 ± 0.6 
 
3.6 ± 0.4 
5294 ± 983.4 
 
   4830 ± 834.6 
3.2 ± 0.7 
 
      5.2 ± 1.6 
 
 
DNA tubes 27.6 ± 1.0 4.1 ± 0.4 5762 ± 728.3 4.4 ± 0.3 
      
 
Dex ODNs 
 
Dexamethasone 
1 µg/ml 
26.8 ± 1.8 
 
     29.0 ± 2.0 
          
4.0 ± 0.4 
 
      3.3 ± 0.3 
6328 ± 1177 
 
   4372 ± 570 
2.4 ± 0.4 
 
      4.9 ± 0.9 
 
 
 
Table 3 Systemic leukocyte counts and microhemodynamic parameters. Systemic leukocyte 
counts as well as microhemodynamic parameters, including inner vessel diameter, blood 
flow velocity, and wall shear rate, were obtained as detailed in Materials and Methods (mean 
± SEM for n= 6 per group). 
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4.3.7 Dexamethasone-conjugated nanoconstructs are 
phagocytosed and stored in endolysosomal 
compartments of tissue-resident cells 
  
Next, the cellular uptake and localization of Dex nanoconstructs in the postischemic 
mouse cremaster muscle was explored by means of in vivo fluorescence microscopy. 
Accordingly, fluorescently labeled Dex tubes, plain tubes, and Dex ODNs were 
concomitantly microinjected with LysoTracker dye in 25 µm to 50 µm distance to a 
postcapillary venule immediately after the release of the vascular clamp. After 60 min 
of reperfusion the muscle has been dissected for further analysis.  
All Dex nanoconstructs were found in the endolysosomal compartment of cells 
present in the postischemic tissue (Fig. 26). As stated above, in the previous 
experiments, tissue-resident macrophages were identified as the population of 
phagocytes, which incorporate CpG nanoconstructs in the cremaster muscle under 
physiologic (Chapter 4.1) as well as under postischemic (Chapter 4.2) conditions. 
The morphology and the localization of cells, which incorporated Dex tubes in the 
postischemic cremaster, strongly suggest that these cells are tissue-resident 
macrophages. 
However, the cellular uptake in the postischemic tissue occurs not within 5 min but 
within 30 min. Since the tissue is considerably damaged within 60 min of reperfusion, 
this might explain the delayed uptake by tissue macrophages, either by a restrained 
diffusion of the nanoconstructs or altered phagocytic preferences of these cells. 
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Fig. 26 Localization of DNA nanoconstructs in the endolysosomes of tissue macrophages. 
Confocal imaging of Dex tubes, DNA tubes, Dex ODNs, and Dex tubes w/o i-motif  
microinjected together with red or green emitting LysoTracker dye into the postischemic 
cremaster muscle. The fluorescence channel images were merged to determine co-
localization (yellow). Images show that Dex tubes (green), DNA nanotubes (green), and Dex 
tubes w/o i-motif (green) were located in the cellular lysosomes (red). Dex ODNs (red) were 
microinjected with green LysoTracker (green) and were also detected in lysosomes. Scale 
bar: 50 µm.  
 
4.3.8 Modulation of VCAM-1 and ICAM-1 expression by 
dexamethasone-conjugated nanoconstructs 
 
One of the described effects of dexamethasone is the downregulation of endothelial 
adhesion molecules including VCAM-1 and ICAM-1 [150, 151]. To determine, 
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whether the downregulation of VCAM-1 and ICAM-1 contributes to the reduction of 
leukocyte transmigration after Dex tube application, immunostainings of postischemic 
cremasteric tissue for VCAM-1 and ICAM-1 and quantifications of the vascular 
expression using confocal microscopy were conducted.  
60 min after application, VCAM-1 was continuously expressed in the 
microvasculature of saline-microinjected tissue, whereas Dex tube application almost 
completely abolished VCAM-1 fluorescence on the endothelium of vessels in close 
proximity to the injection site (Fig. 27A and B). PECAM-1, a marker for endothelial 
junctions [152], served as a vessel marker and there was no obvious effect of DNA 
nanoconstructs on PECAM-1 expression. Microinjection of DNA nanotubes, Dex 
ODNs, and Dex tubes w/o i-motif lowered the VCAM-1 expression on the endothelial 
surface compared to the control group, receiving saline. However, significantly more 
VCAM-1 was expressed on microvessels in these experimental groups than after 
Dex tube injection. Dex ODNs were hardly detectable after 1 h in the postischemic 
cremaster, probably due to degradation within the tissue (Fig. 27 and 28).  
The suppressive effects of Dex tubes on ICAM-1 expression were significantly higher 
compared to the control group, but less pronounced than on VCAM-1 expression. 
Differences of microvascular ICAM-1 expression levels between saline and DNA 
tubes, Dex ODNs, and Dex tubes w/o i-motif-injected tissues could not be observed. 
The two adhesion molecules VCAM-1 and ICAM-1 are important mediators of 
leukocyte firm adhesion and transmigration from the blood into the tissue. The 
downregulation of both molecules after Dex tube injection might contribute to 
decreased influx of leukocytes into the tissue after I/R injury.   
  
Fig. 27 Expression patterns of
postischemic cremaster tissue
(green), VCAM-1 (blue), and 
VCAM-1 expression in vessels 
saline 60 min after application
Dex ODNs into the cremasteric tissue led to equivalent VCAM
after application (A, B). Scale bar: 50 µm
A 
B 
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 VCAM-1 after application of Dex nano
. Confocal immunofluorescence of Dex
PECAM-1 (red) counterstaining showed 
adjacent to the injection site of Dex tubes (
. Injection of DNA tubes, Dex tubes w/o i-
-1 expression levels 60 min 
. 
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 nanoconstructs 
significant lower 
A, B) compared to 
motif as well as of 
  
Fig. 28 Expression patterns of
postischemic cremaster tissue
(green), ICAM-1 (blue), and PECAM
ICAM-1 expression in vessels 
saline 60 min after application
Dex ODNs into the cremasteric tissue 
application (A, B). Scale bar: 50 µm
A 
B 
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 ICAM-1 after application of Dex nano
. Confocal immunofluorescence of Dex
-1 (red) counterstaining showed significant reduction of 
adjacent to the injection site of Dex tubes (
. Injection of DNA tubes, Dex tubes w/o i-
did not affect ICAM-1 expression 60 min after 
. 
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5.1 DNA nanotubes as intracellular delivery vehicles in vivo 
 
Previous studies have proven that self-assembled DNA nanostructures can 
selectively release their payload at the target site and therefore are used as smart 
delivery systems in-vitro [153, 154]. Liedl and coworkers showed that CpG-
conjugated DNA nanotubes, consisting of 30 helices and 62 CpG handles, led to a 
significantly enhanced expression of IL-6 and CD69 on isolated splenocytes 
compared to exposure of CpG ODNs [32]. This study was the basis for a cooperative 
project in the framework of the SFB1032 with the group of Tim Liedl and it was the 
starting point for the in vivo investigations of DNA nanotubes in this thesis.  
In accordance with the previous work of Tim Liedl´s group, it could be demonstrated 
that RAW 264.7 macrophages produced considerably enhanced levels of TNF after 
CpG DNA nanotube exposure, whereas the cellular TNF response to CpG ODNs 
was low, although the applied CpG sequence “concentration” was the same. From 
these results and the performed stability experiments, it can be concluded that DNA 
nanotubes are stable over the course of application until their uptake by 
macrophages. This study also highlights, that complexation of CpG sequences is 
necessary to intensify the cellular TNF release since DNA nanotubes mixed with CpG 
ODNs failed to enhance this immune response. 
These in vitro findings could be confirmed in vivo. Only application of CpG DNA 
tubes, but not the application of CpG ODNs into the murine skeletal muscle did entail 
immunostimulatory effects during the observation period. It has been previously 
described by Wu et al. that the aggregation of CpG ODNs is essential for the 
crosslink of TLR 9 receptors [155] and Kerkmann et al. showed that the formation of 
CpG ODNs to higher-ordered structures enhanced the cellular ability to produce IFN-
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α [156]. Furthermore, linear CpG ODNs are quickly decomposed by exonucleases, 
whereas compaction and linkage to higher structures increases the resistance to 
DNAse substantially [153, 157]. The mechanism of action could be similar in our 
study. The CpG sequences are conjugated in high local densities to the tube 
structure, which could induce effective cross linkage of the TLR 9 receptor, causing 
the release of immunostimulatory mediators in vitro and in vivo.  
Another requirement for the activation of TLR 9 is the cellular uptake of CpG DNA 
nanotubes. Phagocytosis of cellular debris and pathogens is prerequisite for the 
maintenance of tissue homeostasis and immune functions. Tissue-resident 
macrophages are professional phagocytes which fulfill these tasks [158]. It is well 
documented that alveolar macrophages phagocytose metal oxide NPs and as a 
result produce and release cytokines [159, 160]. Interestingly, surface chemistry 
plays a significant role in the uptake of nanomaterials and their pro-inflammatory 
properties. In previous works from our group, it could be demonstrated that solely 
negatively charged quantum dots (QDs) were taken up by perivascular macrophages 
from the bloodstream after intravenous administration and subsequently, leukocytes 
were recruited in mast cell-dependent manner [124, 136]. In a more recent study, we 
observed the rapid uptake of these negatively charged QDs by tissue-resident 
macrophages upon microinjection [161]. The uptake affinity of tissue-resident 
macrophages for negatively charged NPs was confirmed in the present study. 
Negatively charged DNA nanotubes (zeta potential; CpG tube: -13.2 +/- 0.4 mV and 
plain tube: -11.4 +/- 0.2 mV) could be found in the endolysosomes of tissue-resident 
macrophages within 5 min after microinjection.  
In general, there are different routes of internalization by macrophages, such as 
constitutive micropinocytosis and clathrin-mediated uptake [162, 163]. A class of 
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receptors that mediate the endocytosis of pathogens and macromolecules in a 
clathrin-dependent or independent way are scavenger receptors [164, 165]. They are 
known for a rapid clearance of cell debris [166]. Expressed on macrophages, ECs, 
and smooth muscle cells, scavenger receptors recognize and bind negatively 
charged macromolecules, e.g., low-density lipoprotein. King et al. described that the 
scavenger receptor MARCO (macrophage receptor with collagenous structure) 
mediated the uptake of negatively charged, immune-modifying microparticles by 
inflammatory monocytes [167]. Minchin et al. recently showed, that the clearance of 
albumin-covered nanomaterials by macrophages is depending on scavenger receptor 
A1 (SR-A1) and MARCO [168]. The rapid internalization of DNA nanoconstructs, 
irrespective of the presence of a CpG motif, argues for an active uptake process, 
possibly receptor-mediated. The RAGE (receptor for advanced glycation end 
products) receptor, a pattern recognition receptor, is able to bind extracellular DNA 
and delivers it in the endosomal compartment to activate TLR 9 [113, 169]. This 
study could clearly demonstrate the rapid internalization of DNA nanotubes via the 
endolysosomal cellular compartment. The exact pathway of internalization and the 
contribution of specific scavenger or pattern recognition receptors to that process 
require further investigations.  
Apart from macrophages, also mast cells contributed to the CpG DNA nanotube-
induced immune response in the murine muscle tissue. Upon stimulation, mast cells 
release inflammatory mediators such as histamine, platelet-activating factor, or 
TNF from intracellular granula by rapid exocytosis [170, 171].  
The numbers of transmigrated leukocytes upon microinjection of CpG nanotubes 
could be reduced to control levels in the presence of the mast cell stabilisator 
cromolyn [172, 173]. Mast cells, predominantly located in close vicinity to the 
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abluminal side of vessel walls [174], detect macrophage-derived cytokines [175, 176] 
via surface-localized cytokine receptors [129, 177] during the CpG nanotube-elicited 
inflammatory response. The uptake of DNA nanotubes by mast cells could not be 
detected by use of confocal microscopy, but direct mast cell activation can not be 
excluded. Nonetheless, the rapid increase in adherent leukocytes results from the 
amplification of the inflammatory signal cascade initiated by activated mast cells 
[178].  
 
5.2 The impact of CpG DNA nanotubes on I/R injury 
 
Inflammatory responses, initiated by innate immune cells, exert great influence on the 
extent of I/R injury [179]. The induction of this response is predominantly triggered via 
the activation of pattern recognition receptors, specifically TLRs, which are mainly 
expressed by DCs and macrophages. TLR deficiency, as well as preconditioning with 
their ligands has shown to be beneficial in the myocardial I/R model [180-183]. 
Recent studies indicate, that administration of CpG ODNs attenuates cerebral and 
myocardial I/R injuries [116, 184, 185]. Khandoga et al. have demonstrated the 
importance of TLR 2 for the transmigration of leukocytes in the I/R cremaster model 
[186]. Based on these results, the effects of the TLR 9 ligand CpG, conjugated to 
DNA nanoconstructs, on the recruitment of leukocytes in the murine cremaster I/R 
model were investigated. 
The numbers of adherent and transmigrated leukocytes could not be significantly 
lowered by microinjection of CpG DNA nanotubes as compared to CpG ODNs. The 
conjugation of CpG to the DNA tube, which serves as delivery vehicle, could not 
enhance the protective effect of CpG DNA in postischemic tissue. In this context, 
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Zhou and colleagues could show that CpG ODNs bind to the cell surface and the 
immunogenic activity is enhanced at acidic extracellular pH [187] compared to neutral 
pH. During inflammation, the tissue pH is lowered [188, 189] and therefore 
association of unbound CpG ODNs compared to CpG DNA nanotubes might be 
preferred. This might possibly explain the greatly differing effects of CpG ODNs on 
leukocyte recruitment under physiological and pathological conditions. It has recently 
been described by Li et al., that the protective effects of CpG ODNs can be ascribed 
to the activation of the PI3K/AKT pathway, which promotes cell survival [116]. By 
strengthening the survival program of the cell prior to I/R injury, cells seem to be less 
susceptible to intrinsic apoptosis pathways which are triggered by DNA 
fragmentation, a major consequence of ischemia.   
Interestingly, plain DNA tube administration implicated an enhanced transmigration of 
leukocytes. Although DNA has not been described yet as pro-inflammatory under 
ischemic conditions, it is described that the RAGE receptor, which is able to detect 
and bind DNA, mediates vascular injury and inflammation after global cerebral 
ischemia [190]. In our experiments, the externally administered DNA, in the form of 
DNA nanotubes, potentially induces this process. The possible mitigating effects of 
TLR 9 and PI3K/AKT activation due to the presence of CpG sequences in the CpG 
tube-treated experimental group are lacking after microinjection of DNA tubes. 
A major finding was the enormous upregulation of TLR 9 expression and the 
morphological changes of tissue-resident macrophages after microinjection of CpG 
DNA constructs into the postischemic cremaster tissue. Particularly, administration of 
CpG DNA nanotubes resulted in a macrophage phenotype which was characterized 
by long protrusions and a continuous expression of TLR 9 covering the cell bodies. A 
connection between protrusions of different macrophages could not be detected by 
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means of confocal microscopy. Although TLR 9 is considered to be endosomally 
localized, recent publications describe a surface expression of TLR 9 on 
polymorphonuclear leukocytes (PMNLs) [191], splenic DCs [192], and peripheral 
blood mononuclear cells (PBMCs) [193], which are able to differentiate into 
macrophages. The dense “network” of highly ramified macrophages situated close to 
the scrotal cavity, might act as a barrier, similar to macrophages of many internal 
organs such as bladder, gut, peritoneal wall, and diaphragm, where they are 
positioned to build the first line of defense against invading pathogens [194].  
The prevalent expression of TLR 9 in vessels, situated within the ischemic muscle 
tissue might exhibit another defense mechanism. The surface localization of TLR 9 
allows a rapid recognition of pathogens, which is of great importance in essential 
organs, such as the brain. The risk of self-DNA recognition and consequently an 
autoimmune reaction can be minimized through a temporal upregulation or 
presentation of TLR 9, as Wang et al. described [195]. A general upregulation of TLR 
9 in vessels could be observed in all experimental groups, but was pronounced in 
animals that received CpG DNA tubes and CpG ODNs, what might explain the 
susceptibility for the TLR 9 ligand in the I/R cremaster model.   
Macrophages are probing their microenvironment and in response adapt their 
functional phenotype. Their ability to shift the phenotype is reversibly depending on 
the cytokine environment, as previously described by Suttles et al [196]. This 
functional plasticity of macrophages also implicates a morphological plasticity. The 
polarization state of macrophages is reflected by their appearance, since 
proinflammatory (M1) macrophages turn into flat, pancake-like cells whereas 
prohealing (M2) macrophages elongate their cell bodies in an in vitro model [197]. It 
is therefore not surprising, that elongated (possible M2) macrophages appear in the 
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postischemic cremaster tissue, where tissue is highly damaged due to inflammation 
and oxidative stress, triggered by reperfusion. M2 macrophages are contributing to 
the remodeling of the collagen network within the tissue and produce extracellular 
matrix components to promote wound healing processes [198]. Furthermore, the 
activity of M2 macrophages is strongly increased in sterile injuries [199]. Interestingly, 
TLR 9 agonists in combination with adenosine A2A receptor ligands drive 
macrophages efficiently into a M2-like phenotype [200]. Adenosine, released by 
necrotic or apoptotic cells, is characteristic for the starting of the healing phase [201] 
and is recognized by the surface receptor A2A on M2d macrophages [200]. A 
synergistic activity of adenosine and CpG ODNs may also implicate a surface 
localization of TLR 9. Confocal images (Fig. 19) suggest a surface localization of TLR 
9 on CpG DNA nanotube-stimulated CX3CR1-positive macrophages. But further 
investigations are necessary to answer the question, why CpG DNA nanotubes 
induce such an intensive TLR 9 expression in macrophages compared to CpG 
ODNs. Although CpG DNA nanotubes were not able to inhibit the infiltration of 
leukocytes into the ischemic muscle tissue as effective as CpG ODNs, they clearly 
feature an interesting tool to study macrophage morphologies under inflammatory 
conditions.  
 
5.3 Dex tubes as anti-inflammatory agents in vivo 
 
In this set of experiments, DNA nanotubes with amended basic structure were used. 
These newly generated DNA nanotubes consist of 84 nt long ODNs, forming a 6-
helix structure with a length of ~30 nm and a diameter of ~6 nm. The use of 84 nt 
long ODNs enhanced the complementary region and compactness of the structure 
5 Discussion 
 
91 
 
itself. This implies a higher thermal stability, a higher resistance to Mg2+ depletion, 
and obstructed degradation through DNases present in the tissue [202]. DNA 
nanotubes could be detected up to 6 h after incubation within the cellular 
endolysosomes of MH-S macrophages, indicating a high “cellular” stability of the 
constructs, necessary for the successful intracellular delivery of the cargo. The 
environment in ischemic tissue in vivo is characterized by a low pH (pH 6.3-6.6) [203, 
204], low levels of extracellular Mg2+ [205, 206], and elevated levels of DNase I in the 
serum [207, 208]. Despite this detrimental milieu, 6-helix DNA nanotubes were taken 
up by tissue-resident cells and were processed in their endolysosomal compartments 
(Fig. 26). Even though, the uptake was different from that under physiologic 
conditions, the rapid distribution and transport of NPs within a macrophage nanotube 
network, as Rehberg et al. has recently described [161], could also be observed for 
DNA nanotubes which have been microinjected into physiologic muscle tissue (Data 
not shown). This distribution of DNA nanoconstructs in a macrophage “network” was 
reduced in the cremasteric I/R model. Lerchenberger et al. described the remodeling 
and compaction of the collagen network within inflamed tissue [138], maybe causing 
hindered interstitial diffusion and cellular distribution of DNA nanoconstructs. Another 
explanation for the decelerated uptake of Dex nanoconstructs could be a reduced Fc-
mediated phagocytosis and reduced TNF secretion by macrophages at acidic 
extracellular space [209]. Therefore, inflammatory conditions seem to have a great 
impact on the bioavailability of DNA nanoconstructs and the subsequent cellular 
reactions. 
The attachment of folate receptor to the vehicle construct or the use of transfection 
reagent is often necessary for a successful delivery of cargo into target cells [210]. It 
has also been used for the selective delivery of diagnostic agents to activated 
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macrophages [211]. One of the biggest advantages of the DNA nanotube delivery 
system is that such modifications are not necessary to target tissue-resident 
macrophages.  
Conventional therapeutic approaches operate with systemic applications of 
glucocorticoids, causing a bunch of side effects by affecting organs sensitive towards 
GCs, such as heart [212], brain [213], or bones [214]. Unwanted effects such as 
bone loss [215], insulin resistance [216], and sarcopenia [217] do not limit the 
therapeutic use of GCs in arthritis, inflammatory bowel disease, allergy, cancer, or 
transplant rejections. The dexamethasone concentrations used in cell culture and in 
vivo in this study were far lower than the ones therapeutically used and described as 
cytotoxic [142, 218]. But still, even at low concentrations, DNA nanotube-delivered 
dexamethasone revealed its anti-inflammatory impact without harming 
dexamethasone-sensitive cells such as macrophages [219]. Considering this finding 
in a broad context, the dosage of dexamethasone could be reduced by using DNA 
nanotubes as vectors without losing the pharmacological activity by selectively 
targeting inflammatory cells.  
A key reason for the successful delivery of dexamethasone is certainly the pH-
dependent conformational change of the DNA i-motif. Initially, the i-motif was 
discovered in human telomeric and centromeric sequences, as well as in intercalating 
RNA structures and proteins, interacting with cytosine repeats of DNA [220]. 
Nowadays, the i-motif has become an important feature in DNA nanotechnology, 
because it provides additional choices in design, assembly processes, and 
characteristics of DNA-based nanodevices. It has recently been used to fabricate 
nanostructures for the controlled release of small molecules [221] or the mapping of 
pH changes in living cells [222]. It could be demonstrated in vitro that the pH-
5 Discussion 
 
93 
 
sensitive i-motif allows the controlled release of dexamethasone under acidic pH and 
at 37 °C (Fig. 20C). Although endosomal escape of dexamethasone in vivo by means 
of confocal microscopy could not be clearly proven, the data clearly indicate that Dex 
tubes enhanced the inhibition of cytokine production in response to LPS compared to 
a 20 times higher dose of unconjugated dexamethasone, which had no effect on 
leukocyte recruitment in vivo.  
However, Dex tubes w/o i-motif enhanced the inflammatory response in vitro and in 
vivo. This was unexpected and could possibly be explained by the variations in the 
DNA sequence of the i-motif and the non-i-motif DNA tubes. The Dex tubes w/o i-
motif carry a sequence solely consisting of thymine. Golenbock et al. reported that 
adenosine-thymine-rich DNA motifs are highly immunogenic and trigger the 
production of TNF and IL-6 in human and murine cells [223]. How exactly Dex tubes 
w/o i-motif are able to switch to this inflammatory program, needs to be further 
investigated. 
The mechanism of action of dexamethasone is well described and starts with the 
binding to the cytoplasmatic glucocorticoid receptor (GR). The GR undergoes a 
conformational change, allowing the receptor-ligand complex to shuttle into the 
nucleus and actively influence gene transcription [224]. The dexamethasone/GR 
complex is a double-edged sword that is able to facilitate transcription, by binding to 
signal transducer and activator of transcription 5 (STAT5) as well as transrepression 
by preventing the activation of NF-ĸB [225-227]. Since the inflammatory mediator 
TNF is regulated by the activation of NF-ĸB [228] and the TNF response was 
substantially reduced by pretreatment with Dex tubes, the trafficking of delivered 
dexamethasone from the endosome into the nucleus can be assumed.  
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Along with the secretion of TNF, the expression of the cellular adhesion molecules 
VCAM-1 and ICAM-1 on the endothelium was diminished through the 
dexamethasone-induced repression of NF-ĸB [229, 230]. Dex tubes could not be 
detected within endothelial cells by means of in vivo microscopy and confocal 
microscopy, therefore the downregulation of VCAM-1 and ICAM-1 on the endothelial 
surface in postischemic tissue might probably be a “secondary effect”, caused by 
macrophages. Shi and colleagues demonstrated that the expression of endothelial 
cell adhesion molecules is regulated by the inflammatory mediators TNF, IL-6, and 
IFN-γ, derived from macrophages, mast cells, and neutrophils [231]. In this study, 
TNF appeared to be the most potent of these cytokines to change expression levels 
of VCAM-1, ICAM-1, P-selectin, and E-selectin. These results support the view that 
the reduction of VCAM-1 and ICAM-1 after administration of Dex tubes is the result of 
a reduced TNF response. However, a direct Dex tube effect on ECs cannot be ruled 
out. 
TNF overexpression, partly by monocytes or macrophages, is associated with a 
variety of diseases including HIV, cancer, rheumatoid arthritis, and Crohn´s disease 
[232]. TNF−directed therapies are the method of choice in the treatment of 
inflammatory diseases. Therefore, Dex tubes represent a promising nanomedical 
therapeutic alternative to the conventional anti-TNF agents, which cause a multitude 
of side effects due to their ubiquitous biodistribution. Considering the potential clinical 
use of Dex tubes, dose-response-, pharmacokinetics-, and safety-studies need to be 
carried out to outline therapeutic efficacy and applicability. 
In summary, our findings demonstrate that DNA nanotubes allow a cell type-specific 
transport of dexamethasone, which lowers the effective concentration needed to gain 
anti-inflammatory effects.  
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5.4 Conclusion and future perspectives 
 
In conclusion, this study describes a new DNA nanotube approach for the delivery of 
drugs or bioactive molecules into tissue-resident macrophages under physiological 
and pathological conditions.  
Interestingly, DNA nanoconstructs were internalized by macrophages without the use 
of a transfection reagent or the conjugation of target-specific signals or antibodies 
[233]. Compared to other anionic nanomaterials, which need to be modified with 
receptors or signal peptides for cellular uptake [234, 235], DNA nanoconstructs can 
readily be designed for the molecular transportation of drugs or small molecules.  
Although DNA nanoconstruct fluorescence could be detected within the cellular 
endolysosomes, it could not be determined whether the DNA architecture was still 
intact in the cells. Still, the functionality of cargo-carrying nanostructures in the mouse 
model was demonstrated, but for a next generation of DNA nanodevices, for example 
delivering RNA cargo, encoding transcription programs, construct stability, and 
further improvements are of great interest. But not solely stability determines the 
nanomedical development of DNA nanotechnology. These data convey a first 
impression of the distribution of DNA nanotubes and their target cells in vivo, but 
there is a general paucity of information on their long-term effects, immunogenicity 
and clearance. In addition to the understanding of pharmacokinetics and 
biodistribution, the production costs of DNA nanodevices are a major issue. 
Currently, large nanostructures cannot compete with polymer materials in terms of 
production expenses [236]. If DNA nanotechnology is able to overcome these 
challenges, it has the potential to serve as a programmable and multifunctional 
therapeutic system [237].   
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The results of this thesis provide new insights into the localization and the impact of 
DNA-based nanomaterials in vivo and allow for improved development of targeted 
therapies during inflammatory conditions.  
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7.1 Lab equipment and consumables 
 
Table 4 Lab consumables 
Consumables Manufacturer 
1.5 ml and 2 ml tubes  Eppendorf, Hamburg, Germany 
15 ml and 50 ml tubes BD Falcon, Heidelberg, Germany 
Aqua ad injectabilia Braun, Melsungen, Germany 
Baysilone-Paste, hochviskos Bayer, Leverkusen, Germany 
BD Discardit II BD, Heidelberg, Germany 
BD Microlance 3 BD, Heidelberg, Germany 
BD Plastipak BD, Heidelberg, Germany 
Borosilicate micropipettes GB150-TF-8P Science Product, Hofheim, Germany 
Natriumchlorid 0,9 % Lsg. Braun, Melsungen, Germany 
Sterican 100, 0,30 x 12 mm, 30G Braun, Melsungen, Germany 
BD Falcon round bottom tubes  BD, Heidelberg, Germany 
 
Table 5 Lab equipment 
Equipment Manufacturer 
Elektrotom 500-BF KLSMartin, Tuttlingen, Germany  
Eppendorf Research Plus 10, 100, 1000 µl Eppendorf, Hamburg, Germany 
Femtojet microinjector Eppendorf, Hamburg, Germany 
Incubator BD 115 Binder, Tuttlingen, Germany 
Infinite F200 Multiplate reader Tecan, Männedorf, Switzerland 
Gallios flow cytometer Beckman Coulter, Krefeld, Germany 
Leitz Labovert Leica, Wetzlar, Germany 
Patchstar Micromanipulator Scientifica, Uckfield, UK 
PC-10 Puller Narishige, London, UK 
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Pipetboy comfort Integra Biosciences, Ziezers, 
 Switzerland 
Universal 30RF Hettich, Tuttlingen, Germany 
Vortex Genie 2 Bender&Hobein, Zurich, Switzerland 
Coulter ACT Counter Beckman Coulter, Krefeld, Germany 
 
Table 6 Chemicals 
Chemicals Manufacturer 
Cromolyn sodium salt SigmaAldrich, Taufkirchen, Germany 
Dexamethasone SigmaAldrich, Taufkirchen, Germany 
Ketamin Zoetis, Berlin, Germany 
Pentobarbital Merial, Hallbergmoos, Germany 
Xylazin Bayer, Leverkusen, Germany 
 
7.2 Cell culture consumables 
 
Table 7 Cell culture consumables 
Consumable Manufacturer 
Dulbecco´s modified eagle medium Thermo Scientific, Bonn, Germany 
RPMI-1640 medium Merck Millipore, Berlin, Germany 
Phosphate-buffered saline Braun, Melsungen, Germany 
Trypsin-EDTA (0.5 %) Thermo Scientific, Bonn, Germany 
2-Mercaptoethanol (50 mM) Thermo Scientific, Bonn, Germany 
Fetal calf serum Merck Millipore, Berlin, Germany 
Lipopolysaccharides from E. coli SigmaAldrich, Taufkirchen, Germany 
WST-1 Reagent SigmaAldrich, Taufkirchen, Germany 
Mouse TNF-alpha DuoSet ELISA R&D Systems, Wiesbaden, Germany 
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7.3 Immunohistochemistry consumables 
 
Table 8 Primary and secondary antibodies 
Primary or secondary antibody Manufacturer 
Alexa Fluor 488, goat anti rat, IgG (H+L) Life Technologies, Carlsbad, USA 
Alexa Fluor 546, donkey anti goat, IgG (H+L) Life Technologies, Carlsbad, USA 
Alexa Fluor 546, goat anti rabbit, IgG (H+L) Life Technologies, Carlsbad, USA 
Alexa Fluor 633, goat anti rabbit, IgG (H+L) Life Technologies, Carlsbad, USA 
Alexa Fluor 633, goat anti rat, IgG (H+L) Life Technologies, Carlsbad, USA 
CD31, rat, mAb BD, Heidelberg, Germany  
CD45, rat, mAb BioLegend, Fell, Germany 
CD106, rat, mAb BioLegend, Fell, Germany 
F4/80, rat, mAb Abcam, Cambridge, UK 
Glucocorticoid receptor, rabbit, mAb Santa Cruz, Heidelberg, Germany 
Histone H3 (citrulline R2+R8+R17), rabbit, pAb Abcam, Cambridge, UK 
CD45, rat, mAb BioLegend, Fell, Germany 
NF-κB p65 (acetyl K310), rabbit, pAb Abcam, Cambridge, UK 
PECAM-1(M20), goat, mAb Santa Cruz, Heidelberg, Germany 
TLR 9, mouse, mAb Abcam, Cambridge, UK 
TLR 9, rabbit, mAb Abcam, Cambridge, UK 
 
Table 9 Fluorescent dyes  
Fluorescent dye Manufacturer 
FluoSpheres, 2 µm Life Technologies, Carlsbad, USA 
LysoTracker Red DND-99 Life Technologies, Carlsbad, USA 
LysoTracker Green DND-26 Life Technologies, Carlsbad, USA 
TO-PRO-3 Iodid Thermo Scientific, Bonn, Germany 
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Table 10 Microscope equipment and consumables 
Equipment and consumables Manufacturer 
LMPlanFI 20x/0.4 NA Olympus, Münster, Germany 
Plan Apochromat 40x/1.4 NA oil Leica, Wetzlar, Germany 
Plan Apochromat 63x/1.4 NA oil Leica, Wetzlar, Germany 
Plan Apochromat 63x/1.0 NA water Leica, Wetzlar, Germany 
TCS SP5 SMD Leica, Wetzlar, Germany 
Glass coverslips 25 x 25 mm VWR, Radnor, USA 
Rolera EM-C2 cameras Qimaging, Surrey, Canada 
VisiScope A1 imaging system Visitron Systems, Puchheim, 
Germany 
VWR Superfrost Micro Slide VWR, Radnor, USA 
 
Table 11 Consumables  
Consumables Manufacturer 
Paraformaldehyde SigmaAldrich, Taufkirchen, Germany 
PermaFlourTM Aqueous Mounting Medium Beckman Coulter, Krefeld, Germany 
Triton X-100 SigmaAldrich, Taufkirchen, Germany 
Bovine Serum Albumin SigmaAldrich, Taufkirchen, Germany 
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7.4 Abbreviations 
 
3D Three-dimensional 
BSA Bovine serum albumin 
CD Cluster of differentiation 
Csfr1 Colony stimulating factor 1 receptor 
CO2 Carbondioxide 
CoCl2 Cobalt(II)chloride 
CpG -C-phosphate-G- 
cQD carboxyl Quantum Dot 
CX3CR1 CX3 chemokine receptor 1 
Cy3 Cyanine-3 
DAMP  Damage associated pattern 
DC  Dendritic cell 
DCC Dicyclohexylcarbodiimid 
DCM Dichloromethane 
Dex Dexamethasone 
DLS Dynamic light scattering 
DMAP N,N-Dimethylaminopyridine 
DMEM Dulbecco´s modified eagle medium 
DMF Dimethylformamide 
DNA Deoxyribonucleic acid 
dUTP Deoxyuridine-triphosphatase 
ECs  Endothelial cells 
EDTA Ethylenediaminetetraacetic acid 
EGFP Enhanced green fluorescent protein 
Fc Fragment crystallizable region 
FCS Fetal calf serum 
GaAsP Gallium arsenide phosphide 
GC Glucocorticoids 
GR Glucocorticoid receptor 
HPLC High performance liquid chromatography 
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HPSF High purity salt free 
ICAM-1 Intercellular adhesion molecule 1 
IgG Immunoglobulin G 
IL Interleukin 
IFN-α Interferon alpha 
IFN-γ Interferon gamma 
IκB Inhibitor of kappa B 
IKK IκB Kinase 
IR Ischemia/reperfusion 
IRAK Interleukin-1 receptor associated kinase 
kb Kilo-base 
kDa Kilo Dalton 
LPS Lipopolysaccharide 
mAb Monoclonal antibody 
M-CSF Macrophage colony-stimulating factor 
MeOH Methanol 
MES 2-(N-morpholino)ethanesulfonic acid   
MgCl2 Magnesium chloride 
MIP Macrophage inflammatory protein 
MMP Matrixmetalloproteinase 
MWCO Molecular weight cut-off 
MYD88 Myeloid differentiation primary response gene 88 
NaOAc Sodium acetate 
NF-κB Nuclear factor 'kappa-light-chain-enhancer' of activated B- cells 
NOD  Nucleotide-binding oligomerization domain receptor 
NP Nanoparticle 
nt Nucleotides 
ODN Oligodeoxynucleotide 
PAA Polyacrylamid 
pAb Polyclonal antibody 
PAMP  Pathogen associated pattern 
PBMC Peripheral blood mononuclear cell 
PBS Phosphate buffered saline 
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PECAM-1  Platelet endothelial cell adhesion molecule 1 
PFA Para-formaldhehyde 
PMNL Polymorphonuclear leukocyte 
Poly-A Polyadenylation 
STAT5 Signal transducer and activator of transcription 5 
TBE Tris/Borate/EDTA 
TdT Terminal deoxynucleotidyl transferase 
TEM Transmission electron microscopy 
THF Tetrahydrofurane 
TLR  Toll-like receptor 
TNF Tumor necrosis factor 
Tris-HCl Tris hydrochloride 
VCAM-1 Vascular cell adhesion molecule 1 
WST-1 Water soluble tetrazolium salt 1 
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7.5 Publications and presentations 
7.5.1 Publications 
 
Dexamethasone-conjugated DNA nanotubes as anti-inflammatory agents in 
vivo 
Sabine Sellner*, Samet Kocabey*, Tao Zhang, Fritz Krombach, Tim Liedl, Markus 
Rehberg 
Submitted at Biomaterials 
 
Microglial CX3CR1 promotes adult neurogenesis by inhibiting Sirt 1/p65 
signaling independent of CX3CL1 
Sabine Sellner, Paricio-Montesinos Ricardo, Spieß Alena, Masuch Anette, Erny 
Daniel, Harsan Laura A., von Elverfeldt Dominik, Schwabenland Marius, Biber Knut, 
Staszewski Ori, Lira Sergio, Jung Steffen, Prinz Marco, Blank Thomas 
Acta Neuropathologica Communications, 2016 Sep17;4(1):102 
 
Influence of surface modifications on the spatio-temporal microdistribution of 
quantum dots in vivo 
Katharina Nekolla, Kerstin Kick, Sabine Sellner, Karina Mildner, Stefan Zahler, 
Dagmar Zeuschner, Fritz Krombach, Markus Rehberg 
Small, 2016 May;12(19):261-51 
 
Intercellular transport of nanomaterials is mediated by membrane nanotubes in 
vivo 
Markus Rehberg, Anna K. Nekolla, Sabine Sellner, Karina Mildner, Dagmar 
Zeuschner, Fritz Krombach 
Small, 2016 Apr;12(14):1882-90 
 
Multi-photon microscopy of non-fluorescent nanoparticles in vitro and in vivo  
Steffen Dietzel, Stefanie Hermann, Yan Kugel, Sabine Sellner, Bernd Uhl, Stephanie 
Hirn, Fritz Krombach, Markus Rehberg 
Small, 2016 Apr;12(14):3245-57 
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A microfluidics approach to study the accumulation of molecules at basal 
lamina interfaces 
Fabienna Arends, Sabine Sellner, Philipp Seifert, Ulrich Gerland, Markus Rehberg, 
Oliver Lieleg 
Lab on a chip, 2015 Aug 21, 15(16) 
 
DNA nanoconstructs as intracellular delivery vehicles in vivo 
Sabine Sellner*, Samet Kocabey*, Anna K. Nekolla, Fritz Krombach, Tim Liedl, 
Markus Rehberg 
Biomaterials. 2015, 53:453-63 
*These authors contribute equally. 
 
7.5.2 Oral presentations 
 
DNA Nanotubes - Intracellular Delivery Vehicles in vivo 
Sabine Sellner, Samet Kocabey, Fritz Krombach, Tim Liedl, Markus Rehberg 
Emerging Methods and Technologies for Medical Research Conference,  
September 1-2 2015, Stockholm, Sweden 
 
DNA Nanotubes - Intracellular Delivery Vehicles in vivo 
Sabine Sellner, Samet Kocabey, Fritz Krombach, Tim Liedl, Markus Rehberg 
Kolloquium über experimentelle Pathophysiologie  
June 30 2014, Munich, Germany  
 
DNA Nanotubes - Intracellular Delivery Vehicles in vivo 
Sabine Sellner, Samet Kocabey, Fritz Krombach, Tim Liedl, Markus Rehberg 
SFB 1032 Retreat 2014, February 24-25, Frauenchiemsee, Germany  
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7.5.3 Poster presentations 
 
The impact of DNA nanotubes in physiologic and inflamed tissue 
Sabine Sellner, Samet Kocabey, Fritz Krombach, Tim Liedl, Markus Rehberg 
SFB 1032 evaluation 2016, January 28-29, Munich, Germany 
 
Localization and immunogenic properties of DNA nanotubes under 
physiological and pathophysiological conditions 
Sabine Sellner, Samet Kocabey, Fritz Krombach, Tim Liedl, Markus Rehberg 
SFB 1032 Retreat 2015, February 3-5, Altötting, Germany  
 
Localization and immunogenic properties of DNA nanotubes in vivo 
Sabine Sellner, Samet Kocabey, Fritz Krombach, Tim Liedl, Markus Rehberg 
2nd IBN International Symposium Nanomedicine and Nanoassay 2014, December 8-
9, Singapur  
 
Localization and immunogenic properties of DNA nanotubes in vivo 
Sabine Sellner, Samet Kocabey, Fritz Krombach, Tim Liedl, Markus Rehberg 
CeNS Venice Workshop 2014, September 22-26, Venice, Italy 
 
DNA nanotubes as intracellular delivery vehicles in vivo 
Sabine Sellner, Samet Kocabey, Fritz Krombach, Tim Liedl, Markus Rehberg 
International Physics of Living Systems Network Conference 2014, July 21-24, 
Munich, Germany 
 
DNA nanotubes as intracellular delivery vehicles in vivo 
Sabine Sellner, Samet Kocabey, Fritz Krombach, Tim Liedl, Markus Rehberg 
7. International Nanotoxicology Congress 2014, April 23-26, Antalya, Turkey 
 
 
   
